<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2102233281
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2023
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        Ponvory  (Initiation pack)
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        PONESIMOD
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        2,3,4,5,6,7,8,9,10
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Film-coated tablet
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        14
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        NCE
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        36
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        do not store above 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        1628.70
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="JANSSEN PHARMACEUTICA N.V." />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            JANSSEN PHARMACEUTICA N.V.
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 359]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Cigalah Group
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            Janssen-Cilag International NV 
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        L04AA31
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>&nbsp;What Ponvory is</strong></p><p>Ponvory contains the active substance ponesimod. Ponesimod belongs to a group of medicines called sphingosine-1-phosphate (S1P) receptor modulators.</p><p>&nbsp;</p><p><strong>What Ponvory is used for</strong></p><p>Ponvory is used to treat adults with relapsing forms of multiple sclerosis (RMS) with active disease. Active disease in RMS is when there are relapses or when MRI (magnetic resonance imaging) results show signs of inflammation.</p><p>&nbsp;</p><p><strong>What is multiple sclerosis</strong></p><p>Multiple sclerosis (MS) affects the nerves in the brain and spinal cord (the central nervous system).</p><p>&nbsp;</p><p>In MS, the immune system (one of the body&rsquo;s main defence systems) does not work properly. The immune system attacks a protective covering of nerve cells called myelin sheath &ndash; this causes inflammation. This breakdown of the myelin sheath (called demyelination) stops the nerves working properly.</p><p>Symptoms of MS depend on which part of the brain and spinal cord are affected. These can include problems with walking and balance, weakness, numbness, double vision and blurring, poor coordination and bladder problems.</p><p>&nbsp;</p><p>Symptoms of a relapse may disappear completely when the relapse is over &ndash; but some problems may remain.</p><p>&nbsp;</p><p><strong>How Ponvory works</strong></p><p>Ponvory reduces circulating lymphocytes, which are white blood cells involved in the immune system. It does this by keeping them in the lymphoid organs (lymph nodes). This means that fewer lymphocytes are available to attack the myelin sheath around the nerves in the brain and spinal cord.</p><p>&nbsp;</p><p>Decreasing nerve damage in patients with MS reduces the number of attacks (relapses) and slows down worsening of the disease.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Do not take Ponvory if</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; you are allergic to ponesimod or any of the other ingredients of this medicine (listed in section 6).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; your healthcare professional has told you that you have a severely weakened immune system</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; you have had a heart attack, chest pain called unstable angina, stroke or mini-stroke (transient ischaemic attack, TIA), or certain types of heart failure in the last 6 months</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have certain types of heart block (abnormal heart tracing on an ECG (electrocardiogram), usually with a slow heartbeat) or irregular or abnormal heartbeat (arrhythmia), unless you have a pacemaker.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; you have severe active infection or active chronic infection</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; you have active cancer</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; you have moderate or severe liver problems</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; you are pregnant or a woman of childbearing potential not using effective contraception.</p><p>&nbsp;</p><p>If you are not sure if you have any of these apply to you, talk to your doctor before taking Ponvory.</p><p>&nbsp;</p><p><strong>Warnings and precautions</strong></p><p>Talk to your doctor before taking Ponvory if:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; you have an irregular or abnormal or slow heartbeat</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; you have ever had a stroke or other diseases related to blood vessels in the brain</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; you have ever suddenly passed out or fainted (syncope)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; you have a fever or infection</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; you have an immune system that does not work properly due to a disease or taking medicines that weaken your immune system.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; you have never had chickenpox (varicella) or have not received a vaccine for chickenpox. Your doctor may do a blood test for chickenpox virus. You may need to get the full course of vaccine for chickenpox and then wait 1 month before you start taking Ponvory.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; you have breathing problems (such as severe respiratory disease, pulmonary fibrosis or chronic obstructive pulmonary disease)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; you have liver problems</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; you have diabetes. The chance of developing macular oedema (see below) is higher in patients with diabetes.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; you have eye problems &ndash; especially an inflammation of the eye called uveitis</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; you have high blood pressure.</p><p>If any of the above apply to you (or you are not sure), talk to your doctor before taking Ponvory.</p><p>&nbsp;</p><p><strong>Tell your doctor straight away </strong>if you get any of the following side effects while taking Ponvory:</p><p>&nbsp;</p><p><u>Slow heart rate</u> (bradycardia or bradyarrhythmia)</p><p>Ponvory can slow down your heart rate &ndash; especially after you take your first dose. You should have an electrocardiogram (ECG, to check your heart&rsquo;s electrical activity) before you take your first dose of Ponvory or before you restart Ponvory after an interruption in treatment.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you are at increased risk for side effects due to a slowing of your heart rate, your doctor may monitor your heart rate and blood pressure for at least 4 hours after taking your first dose of Ponvory.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; You will also have an ECG at the end of the 4 hours. If you still have a very slow or decreasing heart rate, you may need to be monitored until these have resolved.</p><p>&nbsp;</p><p><u>Infections</u></p><p>&nbsp;</p><p>Ponvory can increase your risk of serious infections that can be life-threatening. Ponvory lowers the number of lymphocytes in your blood. These cells fight infection. Their numbers usually return to normal within 1 week of stopping treatment. Your doctor should review a recent blood test of your blood cells before you start taking Ponvory.</p><p>&nbsp;</p><p>Call your doctor straight away if you have any of these symptoms of an infection during treatment with Ponvory or 1 week after your last dose of Ponvory:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; fever</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; tiredness</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; body aches</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; chills</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; nausea</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; vomiting</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; headache with fever, neck stiffness, sensitivity to light, nausea, confusion, (these may be symptoms of meningitis, an infection of the lining around your brain and spine).</p><p>&nbsp;</p><p><u>Macular oedema</u></p><p>&nbsp;</p><p>Ponvory can cause a problem with your vision called macular oedema (build-up of fluid in the back of the eye (retina) that may cause changes in vision, including blindness).</p><p>&nbsp;</p><p>The symptoms of macular oedema can be similar to vision symptoms of a MS attack (called optic neuritis). Early on, there may not be any symptoms. Be sure to tell your doctor about any changes in your vision. If macular oedema happens, it usually starts in the first 6 months after you start taking Ponvory.</p><p>&nbsp;</p><p>Your doctor should check your vision before you start taking Ponvory and also anytime you notice vision changes during treatment. Your risk of macular oedema is higher if you have diabetes or have had an inflammation of your eye called uveitis.</p><p>&nbsp;</p><p>Call your doctor straight away if you have any of the following:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; blurriness or shadows in the centre of your vision</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; a blind spot in the centre of your vision</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; sensitivity to light</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; unusually coloured (tinted) vision.</p><p>&nbsp;</p><p><u>Liver problems</u></p><p>&nbsp;</p><p>Ponvory may cause liver problems. Your doctor should do blood tests to check your liver function before you start taking Ponvory.</p><p>&nbsp;</p><p>Call your doctor straight away if you have any of the following symptoms of liver problems:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; nausea</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; vomiting</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; stomach pain</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; tiredness</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; loss of appetite</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; your skin or the whites of your eyes turn yellow</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; dark urine.</p><p>&nbsp;</p><p><u>Increased blood pressure</u></p><p>&nbsp;</p><p>As Ponvory can increase your blood pressure, your doctor should check your blood pressure regularly during treatment with Ponvory.</p><p>&nbsp;</p><p><u>Exposure to the sun and protection against the sun</u></p><p>&nbsp;</p><p>As Ponvory may increase the risk of skin cancer, you should limit your exposure to sunlight and UV (ultraviolet) light, by:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; wearing protective clothing</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; regularly applying sunscreen with high sun protection factor.</p><p>&nbsp;</p><p><u>Breathing problems</u></p><p>&nbsp;</p><p>Some people who take Ponvory have shortness of breath. Call your doctor straight away if you have new or worsening breathing problems.</p><p>&nbsp;</p><p><u>Swelling and narrowing of the blood vessels in your brain</u></p><p>&nbsp;</p><p>A condition called PRES (posterior reversible encephalopathy syndrome) has happened with medicines acting similarly to Ponvory. Symptoms of PRES usually improve when you stop taking Ponvory. However, if left untreated, it may lead to a stroke.</p><p>&nbsp;</p><p>Call your doctor straight away if you have any of the following symptoms:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; sudden severe headache</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; sudden confusion</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; sudden loss of vision or other changes in your vision</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; seizure.</p><p>&nbsp;</p><p><u>Worsening of multiple sclerosis after stopping Ponvory</u></p><p>&nbsp;</p><p>When Ponvory is stopped, symptoms of MS may return. They may be worse compared to before or during treatment. Always talk to your doctor before you stop taking Ponvory. Tell your doctor if you have worsening symptoms of MS after stopping Ponvory.</p><p>&nbsp;</p><p><strong>Children and adolescents</strong></p><p>Ponvory has not been studied in children and adolescents, therefore it is not recommended for use in children and adolescents aged less than 18 years.</p><p>&nbsp;</p><p><strong>Other medicines and Ponvory</strong></p><p>Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines including prescription medicines, over-the-counter medicines, vitamins, and herbal supplements.</p><p>Especially tell your doctor if you take:</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; medicines to control your heart rhythm (antiarrhythmics), blood pressure (antihypertensives), or heart beat (such as calcium channel blockers or beta-blockers medicines that may slow your heart rate).</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; medicines that affect your immune system, due to a possible additive effect on the immune system.</p><p>&nbsp;</p><p><strong>Vaccines and Ponvory</strong></p><p>Tell your doctor if you have recently received any vaccinations or if you are planning to receive a vaccination. You should avoid receiving live vaccines during treatment with Ponvory. If you receive a live vaccine, you may get the infection the vaccine was meant to prevent. Ponvory should be stopped 1 week before and for 4 weeks after receiving a live vaccine. Also, other vaccines may not work as</p><p>well when given during treatment with Ponvory.</p><p>&nbsp;</p><p><strong>Pregnancy, contraception, and breast-feeding</strong></p><p>If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor for advice before taking this medicine.</p><p>&nbsp;</p><p><u>Pregnancy</u></p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Do not use Ponvory during pregnancy. If Ponvory is used during pregnancy there is a risk of harm to your unborn baby.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Do not use if you are trying to become pregnant or if you are a woman who could become pregnant and you are not using effective contraception.</p><p>&nbsp;</p><p><u>Women of childbearing potential/Contraception in females</u></p><p>&nbsp;</p><p>If you are a woman of childbearing potential:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Your doctor will inform you about the risk of harm to your unborn baby before you start treatment with Ponvory and you should have a pregnancy test to check that you are not pregnant.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; You must use effective contraception while taking Ponvory and for 1 week after you stop taking it.</p><p>Talk to your doctor about reliable methods of contraception.</p><p>&nbsp;</p><p>If you do become pregnant while taking Ponvory, stop taking Ponvory and tell your doctor straight away.</p><p>&nbsp;</p><p>If you become pregnant within 1 week after you stop taking Ponvory, talk to your doctor. <u>Breast-feeding</u></p><p>You should not breast-feed while you are taking Ponvory. This is to avoid a risk of side effects for the baby since Ponvory may pass into breast milk.</p><p>&nbsp;</p><p><strong>Driving and using machines</strong></p><p>Ponvory is not expected to have an influence on your ability to drive and use machines.</p><p>&nbsp;</p><p><strong>Ponvory contains lactose</strong></p><p>Ponvory contains lactose which is a type of sugar. If you have been told by your doctor that you have an intolerance to some sugars, talk to your doctor before taking this medicine.</p><p>&nbsp;</p><p><strong>Ponvory contains sodium</strong></p><p>This medicine contains less than 1 mmol sodium (23 mg) per tablet, that is to say essentially &lsquo;sodium-free&rsquo;.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Always take this medicine exactly as your doctor has told you. Check with your doctor or pharmacist if you are not sure.</p><p>&nbsp;</p><p><strong>How to take</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Take Ponvory exactly as your doctor tells you. Do not change your dose or stop taking Ponvory unless your doctor tells you to.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Take only 1 tablet each day. </strong>To help you remember to take your medicine you should take it at the same time each day.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Take with or without food.</p><p>&nbsp;</p><p><strong>Treatment initiation pack (14-day)</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Only </strong>start your treatment with Ponvory using the treatment initiation pack, with which your dose will be gradually increased over 14 days. The purpose of the titration phase is to reduce any side effects due to slowing your heart rate at the start of treatment.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Write down the date you start taking the medicine next to day 1 on the Ponvory treatment initiation pack.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Follow this 14-day treatment schedule.</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>Treatment initiation pack</strong></p><p><strong>day</strong></p></td><td style="vertical-align:top"><p><strong>Daily dose</strong></p></td></tr><tr><td style="vertical-align:top"><p>Day 1</p></td><td style="vertical-align:top"><p>2 mg</p></td></tr><tr><td style="vertical-align:top"><p>Day 2</p></td><td style="vertical-align:top"><p>2 mg</p></td></tr><tr><td style="vertical-align:top"><p>Day 3</p></td><td style="vertical-align:top"><p>3 mg</p></td></tr><tr><td style="vertical-align:top"><p>Day 4</p></td><td style="vertical-align:top"><p>3 mg</p></td></tr><tr><td style="vertical-align:top"><p>Day 5</p></td><td style="vertical-align:top"><p>4 mg</p></td></tr><tr><td style="vertical-align:top"><p>Day 6</p></td><td style="vertical-align:top"><p>4 mg</p></td></tr><tr><td style="vertical-align:top"><p>Day 7</p></td><td style="vertical-align:top"><p>5 mg</p></td></tr><tr><td style="vertical-align:top"><p>Day 8</p></td><td style="vertical-align:top"><p>6 mg</p></td></tr><tr><td style="vertical-align:top"><p>Day 9</p></td><td style="vertical-align:top"><p>7 mg</p></td></tr><tr><td style="vertical-align:top"><p>Day 10</p></td><td style="vertical-align:top"><p>8 mg</p></td></tr><tr><td style="vertical-align:top"><p>Day 11</p></td><td style="vertical-align:top"><p>9 mg</p></td></tr><tr><td style="vertical-align:top"><p>Day 12</p></td><td style="vertical-align:top"><p>10 mg</p></td></tr><tr><td style="vertical-align:top"><p>Day 13</p></td><td style="vertical-align:top"><p>10 mg</p></td></tr><tr><td style="vertical-align:top"><p>Day 14</p></td><td style="vertical-align:top"><p>10 mg</p></td></tr></tbody></table><p>&nbsp;</p><p><strong>Maintenance dose</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>After </strong>you finish taking the tablets in the treatment initiation pack, continue treatment using the 20 mg maintenance dose.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Write down the date you start taking the 20 mg maintenance dose, next to week 1 of the Ponvory 20 mg blister pack.</p><p>&nbsp;</p><p><strong>If you take more Ponvory than you should</strong></p><p>If you have taken more Ponvory than you should, call your doctor straight away or go to a hospital straight away. Take the medicine pack and this package leaflet with you.</p><p>&nbsp;</p><p><strong>If you forget to take Ponvory</strong></p><p>Do not take a double dose to make up for a forgotten tablet.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you miss taking up to 3 Ponvory tablets in a row, while taking the treatment initiation pack or the maintenance dose, you can continue treatment by taking the <strong>first </strong>dose you missed. Take&nbsp;<strong>1 </strong>tablet as soon as you remember, then take 1 tablet a day to continue with the treatment initiation pack dose or maintenance dose as planned.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you miss 4 or more Ponvory tablets in a row, while taking the treatment initiation pack or the maintenance dose, you need to restart treatment with a new 14-day treatment initiation pack. Call your doctor straight away if you miss 4 or more doses of Ponvory.</p><p>Write down the date you start taking the medicine so you will know if you miss 4 or more doses in a row.</p><p>&nbsp;</p><p><strong>Do not stop taking Ponvory without talking with your doctor first.</strong></p><p>Do not restart Ponvory after stopping it for 4 or more days in a row without seeking advice from your doctor. You will need to restart your treatment with a new treatment initiation pack.</p><p>&nbsp;</p><p>If you have any further questions on the use of this medicine, ask your doctor or pharmacist.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them.</p><p>&nbsp;</p><p><u>Some side effects could be or could become <strong>serious</strong></u></p><p>Tell your doctor or pharmacist immediately if you notice any of the side effects listed below because they may be signs of serious effects:</p><p>&nbsp;</p><p><strong>Common </strong>(may affect up to 1 in 10 people)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; urinary tract infection</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; bronchitis</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; flu (influenza)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; viral infection of nose, throat, or chest (viral respiratory tract infection)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; viral infection</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; herpes zoster virus infection (shingles)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; lung infection (pneumonia)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; spinning sensation (vertigo)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; fever (pyrexia)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; build-up of fluid in the back of the eye (retina) that may cause changes in vision, including blindness (macular oedema)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; fits (seizures)</p><p>&nbsp;</p><p><strong>Uncommon </strong>(may affect up to 1 in 100 people)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; slow heart beat (bradycardia)<u> Other side effects</u></p><p><strong>Very common </strong>(may affect more than 1 in 10 people)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; infection of the nose, sinuses, or throat (nasopharyngitis, respiratory tract infection)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; increased level of liver enzymes in the blood (a sign of liver problems)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; low number of a type of white blood cell, called lymphocytes (lymphopenia)</p><p>&nbsp;</p><p><strong>Common </strong>(may affect up to 1 in 10 people)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; high blood pressure (hypertension)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; back pain</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; feeling very tired (fatigue)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; feeling dizzy</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; being short of breath (dyspnoea)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; high level of cholesterol in the blood (hypercholesterolaemia)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; joint pain (arthralgia)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; arm or leg pain</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; depression</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; difficulty sleeping (insomnia)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; cough</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; itchy, runny, or blocked nose (rhinitis), infected or irritated throat (pharyngitis, laryngitis), sinus infection (sinusitis)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; feeling anxious (anxiety)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; decreased feeling or sensitivity, especially in the skin (hypoaesthesia)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; increased level of a protein in the blood that may indicate an infection or inflammation (C-reactive protein increased)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; feeling sleepy (somnolence)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; indigestion (dyspepsia)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; swollen hands, ankles, or feet (peripheral oedema)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; migraine</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ligament sprain</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; chest discomfort</p><p>&nbsp;</p><p><strong>Uncommon </strong>(may affect up to 1 in 100 people)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; high level of potassium in the blood (hyperkalaemia)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; swollen joint</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; dry mouth</p><p>&nbsp;</p><p><strong>Reporting of side effects</strong></p><p>If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. By reporting side effects, you can help provide more information on the safety of this medicine.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Keep this medicine out of the sight and reach of children.</p><p>&nbsp;</p><p>Do not use this medicine after the expiry date which is stated on the carton and blister foil after EXP. The expiry date refers to the last day of that month.</p><p>&nbsp;</p><p>Don&rsquo;t store above 30 <sup>o</sup> C</p><p>&nbsp;</p><p>Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>&nbsp;What Ponvory contains</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The active substance is ponesimod</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The other excipients are:</p><p>&nbsp;</p><p><u>Tablet core</u></p><p>&nbsp;</p><p>Croscarmellose sodium, lactose monohydrate (see &ldquo;Ponvory contains lactose&rdquo;), magnesium stearate, microcrystalline cellulose, Povidone K30, silica colloidal anhydrous and sodium laurilsulfate.</p><p>&nbsp;</p><p><u>Tablet coating</u></p><p>&nbsp;</p><p>Hypromellose 2910, lactose monohydrate, Macrogol 3350, titanium dioxide and triacetin.</p><p>&nbsp;</p><p><em>Ponvory 3 mg film-coated tablets</em></p><p>Iron oxide red (E172) and iron oxide yellow (E172)</p><p>&nbsp;</p><p><em>Ponvory 4 mg film-coated tablets</em></p><p>Iron oxide red (E172) and black iron oxide (E172)</p><p>&nbsp;</p><p><em>Ponvory 5 mg film-coated tablets</em></p><p>Black iron oxide (E172) and iron oxide yellow (E172)</p><p>&nbsp;</p><p><em>Ponvory 7 mg film-coated tablets</em></p><p>Iron oxide red (E172) and iron oxide yellow (E172)</p><p>&nbsp;</p><p><em>Ponvory 8 mg film-coated tablets</em></p><p>Iron oxide red (E172) and black iron oxide (E172)</p><p>&nbsp;</p><p><em>Ponvory 9 mg film-coated tablets</em></p><p>Iron oxide red (E172) and black iron oxide (E172), iron oxide yellow (E172)</p><p>&nbsp;</p><p><em>Ponvory 10 mg film-coated tablets</em></p><p>Iron oxide red (E172) and iron oxide yellow (E172)</p><p>&nbsp;</p><p><em>Ponvory 20 mg film-coated tablets</em></p><p>Iron oxide yellow (E172)</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                What Ponvory looks like and contents of the pack
Ponvory 2 mg film-coated tablets are white, round, biconvex, film-coated tablet of 5 mm diameter with “2” on one side and an arch on the other side.

Ponvory 3 mg film-coated tablets are red, round, biconvex, film-coated tablet of 5 mm diameter with “3” on one side and an arch on the other side.

Ponvory 4 mg film-coated tablets are purple, round, biconvex, film-coated tablet of 5 mm diameter with “4” on one side and an arch on the other side.

Ponvory 5 mg film-coated tablets are green, round, biconvex, film-coated tablet of 8.6 mm diameter with “5” on one side and an arch and an “A” on the other side.

Ponvory 6 mg film-coated tablets are white, round, biconvex, film-coated tablet of 8.6 mm diameter with “6” on one side and an arch and an “A” on the other side.

Ponvory 7 mg film-coated tablets are red, round, biconvex, film-coated tablet of 8.6 mm diameter with “7” on one side and an arch and an “A” on the other side.

Ponvory 8 mg film-coated tablets are purple, round, biconvex, film-coated tablet of 8.6 mm diameter with “8” on one side and an arch and an “A” on the other side.

Ponvory 9 mg film-coated tablets are brown, round, biconvex, film-coated tablet of 8.6 mm diameter with “9” on one side and an arch and an “A” on the other side.

Ponvory 10 mg film-coated tablets are orange, round, biconvex, film-coated tablet of 8.6 mm diameter with “10” on one side and an arch and an “A” on the other side.

Ponvory 20 mg film-coated tablets are yellow, round, biconvex, film-coated tablet of 8.6 mm diameter with “20” on one side and an arch and an “A” on the other side.

Ponvory treatment initiation pack (wallet configuration)

Each blister pack of 14 film-coated tablets for a 2-week treatment schedule contains: 2 film-coated tablets of 2 mg
2 film-coated tablets of 3 mg
2 film-coated tablets of 4 mg
1 film-coated tablet of 5 mg
1 film-coated tablet of 6 mg
1 film-coated tablet of 7 mg
1 film-coated tablet of 8 mg
 
1 film-coated tablet of 9 mg
3 film-coated tablets of 10 mg

Ponvory 20 mg film-coated tablets (maintenance pack) (wallet configuration)

Pack containing 28 film-coated tablets for a 4-week treatment schedule. Not all pack sizes may be marketed.

To contact us, go to www.janssen.com/contact-us
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Marketing Authorisation Holder</strong></p><p>Janssen-Cilag International NV Turnhoutseweg 30</p><p>B-2340 Beerse Belgium</p><p>&nbsp;</p><p><strong>Manufacturer</strong></p><p>Patheon France 40, boulevard de Champaret 38300 Bourgoin Jallieu, France</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                This leaflet was last revised in 5-July-2023 
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL"><strong>ما</strong><strong> </strong><strong>دواء</strong><strong> </strong><strong>بونفوري</strong></p><p dir="RTL">يحتوي دواء بونفوري على المادة الفعالة &quot;بونيسيمود&quot;، تنتمي المادة الفعالة &quot;بونيسيمود&quot; إلى مجموعة من الأدوية تسمى مُعدِّلات مستقبلات</p><p dir="RTL">.)S1P( سفينغوزين - 1 فوسفات</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>استخدامات</strong><strong> </strong><strong>دواء</strong><strong> </strong><strong>بونفوري</strong></p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL">المصاحب للمرض النشط. يتمثل المرض النشط )RMS ( يستخدم دواء بونفوري لعلاج البالغين الذين يعانون من التصلب المتعدد الانتكاسي</p><p dir="RTL">&nbsp;</p><p dir="RTL">علامات على الالتهاب . )MRI( للتصلب المتعدد الانتكاسي في حدوث الانتكاسات، أو عندما تظهر نتائج التصوير بالرنين المغناطيسي</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>ما</strong><strong> </strong><strong>التصلب</strong><strong> </strong><strong>المتعدد</strong><strong> </strong><strong>؟</strong></p><p dir="RTL">في أعصاب الدماغ والحبل الشوكي (الجهاز العصبي المركزي). )MS( يؤثر التصلب المتعدد</p><p dir="RTL">عند الإصابة بمرض التصلب المتعدد، لا يعمل الجهاز المناعي (أحد أنظمة الدفاع الرئيسية في الجسم) بشكل صحيح. ففيه يهاجم الجهاز المناعي الغلاف الواقي للخلايا العصبية المسمى غشاء الميالين؛ وهذا ما يسبب الالتهاب. هذا التدهور الذي يصيب غشاء الميالين (يسمى زوال الميالين) يوقف عمل الأعصاب بشكل صحيح.</p><p dir="RTL">&nbsp;</p><p dir="RTL">تعتمد أعراض مرض التصلب المتعدد على الجزء المصاب من الدماغ والحبل الشوكي. يمكن أن تشمل الأعراض وجود مشاكل في المشي</p><p dir="RTL">والتوازن، والضَّعف، والتنميل، وازدواج الرؤية وضبابيتها، وضعف التناسق العضلي، ومشاكل المثانة.</p><p dir="RTL">&nbsp;</p><p dir="RTL">قد تختفي أعراض الانتكاس تمامًا عند انتهائه، ولكن قد تظل بعض المشكلات قائمة.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>كيف</strong><strong> </strong><strong>يعمل</strong><strong> </strong><strong>دواء</strong><strong> </strong><strong>بونفوري</strong></p><p dir="RTL">يقلل دواء بونفوري من انتشار الخلايا الليمفاوية، وهي خلايا الدم البيضاء التي تشكل جزءًا من جهاز المناعة. ويتحقق ذلك عن طريق إبقاء تلك الخلايا داخل الأعضاء الليمفاوية (العقد الليمفاوية). وهذا يعني تقليل عدد الخلايا الليمفاوية التي تهاجم غشاء الميالين المحيط بالأعصاب في الدماغ والحبل الشوكي.</p><p dir="RTL">&nbsp;</p><p dir="RTL">إن تقليل تلف الأعصاب لدى مرضى التصلب المتعدد يحد من عدد النوبات (الانتكاسات) التي تصيبهم ويبطئ من تفاقم المرض.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">&nbsp;</p><p dir="RTL"><strong>لا</strong><strong> </strong><strong>تتناول</strong><strong> </strong><strong>دواء</strong><strong> </strong><strong>بونفوري</strong><strong> </strong><strong>في</strong><strong> </strong><strong>الحالات</strong><strong> </strong><strong>التالية</strong></p><p dir="RTL">&bull; إذا كنت تعاني من حساسية تجاه مادة بونيسيمود أو أي من المكونات الأخرى في هذا الدواء (مذكورة في القسم ٦).</p><p dir="RTL">&bull; إذا أخبرك مختص الرعاية الصحية أنك تعاني من ضعف شديد في جهاز المناعة</p><p dir="RTL">&bull; إذا أصبت بذبحة قلبية، أو ألم في الصدر يسمى الذبحة الصدرية غير المستقرة، أو سكتة دماغية أو سكتة دماغية صغرى (نوبة إقفارية</p><p dir="RTL">عابرة ، &nbsp;(TIA أو أنواع معينة من السكتة القلبية خلال ٦ أشهر ماضية</p><p dir="RTL">&nbsp;&bull; إذا كنت تعاني من أنواع معينة من اضطراب كهرباء القلب ( رسم غير طبيعي للقلب على جهاز ECG (الرسم الكهربي للقلب) مصحوب عادةً ببطء في ضربات القلب)، أو من ضربات قلب غير منتظمة أو غير طبيعية (اضطرا ب ضربات القلب) إلا إذا كنت تستخدم جهاز تنظيم ضربات القلب.</p><p dir="RTL">&bull; إذا كانت لديك عدوى نشطة شديدة أو مزمنة</p><p dir="RTL">&bull; إذا كنت مصابًا بسرطان نشط</p><p dir="RTL">&bull; إذا كنت تعاني من مشكلة متوسطة أو شديدة في الكبد</p><p dir="RTL">&bull; إذا كن ت حاملاً أو في سن الإنجاب ولا تستخدمين وسيلة منع حمل فعالة.</p><p dir="RTL">إذا لم تكن متأكدًا من انطباق أي من المذكور أعلاه عليك، فتحدث إلى طبيبك قبل تناول دواء بونفوري.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>التحذيرات</strong><strong> </strong><strong>والاحتياطات</strong></p><p dir="RTL">تحدث إلى طبيبك قبل تناول دواء بونفوري إذا:</p><p dir="RTL">&bull; كانت ضربات قلبك غير منتظمة أو غير طبيعية أو بطيئة</p><p dir="RTL">&bull; أصبت من قبل بسكتة دماغية أو بأمراض أخرى متعلقة بالأوعية الدموية في الدماغ</p><p dir="RTL">&bull; سبق وأغشي عليك فجأة أو فقدت وعيك (إغماء(</p><p dir="RTL">&bull; كنت مصابًا بحمى أو عدوى</p><p dir="RTL">&bull; كان جهازك المناعي يواجه قصورًا وظيفيًا بسبب مرض أو تناول أدوية تضعفه.</p><p dir="RTL">&bull; لم تسبق لك الإصابة بجدري الماء (الحماق) أو لم تحصل على لقاح جدري الماء. قد يُجري لك طبيبك فحص دم للكشف عن فيروس جدري الماء. وقد تحتاج إلى الحصول على الجرعة الكاملة للقاح ضد جدري الماء ثم الانتظار لمدة شهر واحد قبل البدء في تناول دواء بونفوري.</p><p dir="RTL">&bull; كنت تعاني من مشاكل في التنفس (مثل أمراض الجهاز التنفسي الشديدة، أو تليف رئوي، أو مرض الانسداد الرئوي المزمن( .</p><p dir="RTL">&bull; كنت تعاني من مشكلات في الكبد</p><p dir="RTL">&bull; كنت تعاني من داء السكري. وتكون احتمالية الإصابة بالوذمة البقعية (انظر أدناه) أعلى لدى مرضى السكري.</p><p dir="RTL">&bull; كانت لديك مشاكل في العين، وخاصة الالتهاب المسمى بالتهاب القزحية</p><p dir="RTL">&bull; كنت تعاني من ارتفاع ضغط الدم.</p><p dir="RTL">إذا كانت أي من الحالات المذكورة أعلاه تنطبق عليك (أو كنت غير متأكد)، فاستشر طبيبك قبل تناول دواء بونفوري.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>أخبر</strong><strong> </strong><strong>طبيبك</strong><strong> </strong><strong>على</strong><strong> </strong><strong>الفور</strong><strong> </strong>إذا أصبت بأي من الآثار الجانبية التالية في أثناء تناولك لدواء بونفوري:</p><p dir="RTL">&nbsp;</p><p dir="RTL"><u>انخفاض</u><u> </u><u>معدل</u><u> </u><u>ضربات</u><u> </u><u>القلب</u><u> (</u><u>بطء</u><u> </u><u>القلب</u><u> </u><u>أو</u><u> </u><u>تباطؤ</u><u> </u><u>ضربات</u><u> </u><u>القلب</u><u>(</u></p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;بإمكان دواء بونفوري أن يبطئ معدل ضربات القلب، وخاصة بعد تناول جرعتك الأولى. يجب أن تُجري رسمًا كهربيًا للقلب &nbsp;(ECG ،</p><p dir="RTL">للتحقق من النشاط الكهربي لقلبك) قبل أن تتناول جرعتك الأولى من دواء بونفوري أو قبل استئناف دواء بونفوري بعد انقطاع العلاج.</p><p dir="RTL">&bull; إذا كنت معرضًا لخطر أكبر من الإصابة بآثار جانبية بسبب انخفاض معدل ضربات القلب، فقد يلجأ طبيبك لمراقبة معدل ضربات القلب</p><p dir="RTL">وضغط الدم لمدة ٤ ساعات على الأقل بعد تناول جرعتك الأولى من دواء بونفوري.</p><p dir="RTL">&bull; ستجري أيضًا رسمًا كهربيًا للقلب بعد انتهاء الساعات الأربع. إذا كنت لا تزال تعاني من بطء أو انخفاض شديد في معدل ضربات القلب،</p><p dir="RTL">فقد تحتاج إلى الخضوع للمراقبة حتى تزول المشكلة.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><u>العدوى</u></p><p dir="RTL"><u>&nbsp;</u></p><p dir="RTL">بإمكان دواء بونفوري أن يزيد خطر إصابتك بعدوى خطيرة تهدد حياتك. فدواء بونفوري يقلل من عدد الخلايا الليمفاوية في دمك.</p><p dir="RTL">وهذه الخلايا مسؤولة عن مقاومة العدوى. عادة ما تعود أعداد هذه الخلايا إلى طبيعتها في خلال أسبوع واحد من التوقف عن العلاج.</p><p dir="RTL">وينبغي لطبيبك أن يراجع فحص دم حديث لخلايا دمك قبل البدء في تناول دواء بونفوري .</p><p dir="RTL">&nbsp;</p><p dir="RTL">اتصل بطبيبك على الفور إذا ظهرت عليك أي من هذه الأعراض الدالة على العدوى، في أثناء العلاج بدواء بونفوري، أو بعد أسبوع</p><p dir="RTL">واحد من آخر جرعة من دواء بونفوري :</p><p dir="RTL">&bull; الحمى</p><p dir="RTL">&bull; الشعور بالتعب.</p><p dir="RTL">&bull; آلام الجسم</p><p dir="RTL">&bull; القشعريرة</p><p dir="RTL">&bull; الغثيان</p><p dir="RTL">&bull; التقيؤ</p><p dir="RTL">&bull; صداع مع حمى، تصلب في الرقبة، حساسية للضوء، غثيان، تشوش (قد تدل هذه الأعراض على التهاب السحايا، أو التهاب البطانة</p><p dir="RTL">المحيطة بالدماغ والعمود الفقري(.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><u>الوذمة</u><u> </u><u>البقعية</u></p><p dir="RTL">يمكن أن يسبب دواء بونفوري مشكلة في قدرتك على الرؤية تسمى الوذمة البقعية (تراكم السوائل في الجزء الخلفي من العين (الشبكية) وقد تسبب تغيرات في الرؤية تشمل فقدان البصر(.</p><p dir="RTL">من الممكن أن تشبه أعراض الوذمة البقعية أعراض الرؤية المصاحبة لنوبة تصلب متعدد (وتسمى بالتهاب العصب البصري). وقد لا تظهر أي أعراض في بداية التناول. تأكد من إبلاغ طبيبك بأي تغييرات تطرأ على رؤيتك. إذا حدث وأصبت بالوذمة البقعية، فعادةً ما تبدأ في أول ٦ أشهر من بعد البدء في تناول دواء بونفوري.</p><p dir="RTL">&nbsp;</p><p dir="RTL">ينبغي لطبيبك أن يتحقق من رؤيتك قبل أن تبدأ في تناول دواء بونفوري، وأيضًا في أي وقت تلاحظ فيه حدوث تغيرات على الرؤية في أثناء العلاج.</p><p dir="RTL">ويزداد خطر الإصابة بالوذمة البقعية إذا كنت مصابًا بداء السكري أو بالتهاب في العين يسمى التهاب القزحية.</p><p dir="RTL">&nbsp;</p><p dir="RTL">اتصل بطبيبك على الفور إذا لاحظت أيًّا من المشكلات التالية:</p><p dir="RTL">&bull; الضبابية أو ظهور ظلال في مركز الرؤية</p><p dir="RTL">&bull; بقعة عمياء في مركز الرؤية</p><p dir="RTL">&bull; حساسية للضوء</p><p dir="RTL">&bull; رؤية ملونة غير اعتيادية.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><u>مشكلات</u><u> </u><u>في</u><u> </u><u>الكبد</u></p><p dir="RTL">&nbsp;</p><p dir="RTL">قد يسبب دواء بونفوري مشكلات في الكبد. ينبغي لطبيبك إجراء فحوصات الدم لفحص وظائف الكبد قبل أن تبدأ في تناول دواء</p><p dir="RTL">بونفوري .</p><p dir="RTL">&nbsp;</p><p dir="RTL">اتصل على طبيبك على الفور إذا لاحظت أيًّا من الأعراض التالية الدالة على مشكلات الكبد :</p><p dir="RTL">&bull; الغثيان</p><p dir="RTL">&bull; التقيؤ</p><p dir="RTL">&bull; آلام في المعدة</p><p dir="RTL">&bull; الشعور بالتعب.</p><p dir="RTL">&bull; فقدان الشهية</p><p dir="RTL">&bull; اصفرار الجلد أواصفرار بياض العينين</p><p dir="RTL">&bull; البول الداكن.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><u>ارتفاع</u><u> </u><u>ضغط</u><u> </u><u>الد</u><u> </u><u>م</u></p><p dir="RTL">&nbsp;</p><p dir="RTL">نظرًا لقدرة دواء بونفوري على رفع ضغط الدم، ينبغي لطبيبك فحص ضغط دمك بانتظام أثناء العلاج باستخدام دواء بونفوري .</p><p dir="RTL">&nbsp;</p><p dir="RTL"><u>التعرض</u><u> </u><u>لأشعة</u><u> </u><u>الشمس</u><u> </u><u>والحماية</u><u> </u><u>منها</u></p><p dir="RTL">&nbsp;</p><p dir="RTL">نظرًا لأن دواء بونفوري قد يزيد من خطر الإصابة بسرطان الجلد، ينبغي لك الحد من تعرضك لأشعة الشمس والأشعة فوق البنفسجية</p><p dir="RTL">UV)) ، من خلال :</p><p dir="RTL">&bull; ارتداء الملابس الواقية</p><p dir="RTL">&bull; وضع كريم واقٍ من الشمس بعامل حماية عالٍ بانتظام.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><u>مشكلات</u><u> </u><u>في</u><u> </u><u>التنفس</u></p><p dir="RTL">&nbsp;</p><p dir="RTL">يعاني بعض الأشخاص الذين يتناولون دواء بونفوري من ضيق النفس. اتصل بطبيبك على الفور إذا أصبت بمشكلات تنفس مستجدة أو</p><p dir="RTL">إذا تفاقمت المشكلات .</p><p dir="RTL">&nbsp;</p><p dir="RTL"><u>تورم</u><u> </u><u>وضيق</u><u> </u><u>الأوعية</u><u> </u><u>الدموية</u><u> </u><u>في</u><u> </u><u>الدماغ</u></p><p dir="RTL">حدثت حالة مرضية تسمى PRES متلازمة الاعتلال الدماغي الخلفي المعكوس( مع الأدوية التي تعمل بشكل مشابه لدواء بونفوري. (</p><p dir="RTL">وعادةً ما تتحسن أعراض PRES عند التوقف عن تناول دواء بونفوري. ومع ذلك، إذا تُركت هذه الحالة المرضية دون علاج، فقد تؤدي إلى سكتة دماغية.</p><p dir="RTL">&nbsp;</p><p dir="RTL">اتصل بطبيبك على الفور إذا لاحظت أيًّا من الأعراض التالية :</p><p dir="RTL">&bull; صداع شديد مفاجئ</p><p dir="RTL">&bull; تشوش مفاجئ</p><p dir="RTL">&bull; فقدان مفاجئ للرؤية أو غير ذلك من التغيرات على رؤيتك</p><p dir="RTL">&bull; نوبة صرع</p><p dir="RTL">&nbsp;</p><p dir="RTL"><u>تفاقم</u><u> </u><u>مرض</u><u> </u><u>التصلب</u><u> </u><u>المتعدد</u><u> </u><u>بعد</u><u> </u><u>إيقاف</u><u> </u><u>دواء</u><u> </u><u>بونفوري</u></p><p dir="RTL">&nbsp;</p><p dir="RTL">قد تعاودك أعراض مرض التصلب المتعدد عند التوقف عن تناول دواء بونفوري. وقد تكون الأعراض أسوأ مما كانت عليه قبل</p><p dir="RTL">العلاج أو خلاله. احرص دومًا على استشارة طبيبك قبل التوقف عن تناول دواء بونفوري. أخبر طبيبك إذا كنت تعاني من تفاقم</p><p dir="RTL">أعراض مرض التصلب المتعدد بعد التوقف عن تناول دواء بونفوري .</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>الأطفال</strong><strong> </strong><strong>والمراهقون</strong></p><p dir="RTL">لم يخضع دواء بونفوري للدراسة على الأطفال والمراهقين، لذلك لا يُنصح باستخدامه للأطفال والمراهقين الذين تقل أعمارهم عن</p><p dir="RTL">&nbsp;١٨ عامًا</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>الأدوية</strong><strong> </strong><strong>الأخرى</strong><strong> </strong><strong>ودواء</strong><strong> </strong><strong>بونفوري</strong></p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL">أخبر طبيبك أو الصيدلي إذا كنت تتناول، أو تناولت مؤخرًا، أو قد تتناول، أي أدوية أخرى، بما في ذلك الأدوية ذات الوصفة العلاجية، والأدوية التي لا تستلزم وصفة علاجية، والفيتامينات والمكملات العشبية. أخبر طبيبك وخاصة إذا كنت تتناول أيًّا مما يلي:</p><p dir="RTL">&bull; أدوية للتحكم في ضربات القلب (مضادات تسارع ضربات القلب)، أو ضغط الدم (الأدوية الخافضة للضغط)، أو ضربات القلب (مثل</p><p dir="RTL">حاصرات قنوات الكالسيوم أو أدوية حاصرات بيتا التي قد تبطئ معدل ضربات القلب(.</p><p dir="RTL">&bull; أدوية تؤثر في جهازك المناعي، بسبب تأثيرها الإضافي المحتمل في جهاز المناعة.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>اللقاحات</strong><strong> </strong><strong>ودواء</strong><strong> </strong><strong>بونفوري</strong></p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL">أخبر طبيبك إذا كنت قد تلقيت مؤخرًا أي لقاحات، أو كنت تخطط لتلقي لقاح. ينبغي لك تجنب تلقي اللقاحات الحية في أثناء العلاج مع دواء</p><p dir="RTL">بونفوري. فإذا تلقيت لقاحًا حيًا، فقد تصاب بالعدوى التي كان من المفترض أن يمنعها اللقاح. وينبغي إيقاف تناول دواء بونفوري قبل أسبوع واحد من تلقي لقاح حي، ولمدة 4 أسابيع من بعد تلقيه. قد لا تعمل اللقاحات الأخرى أيضًا جيدًا عند إعطائها خلال العلاج باستخدام دواء</p><p dir="RTL">بونفوري .</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الحمل،</strong><strong> </strong><strong>ووسائل</strong><strong> </strong><strong>منع</strong><strong> </strong><strong>الحمل،</strong><strong> </strong><strong>والرضاعة</strong><strong> </strong><strong>الطبيعية</strong></p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL">إذا كنت حاملاً أو ترضعين، أو تعتقدين أنك قد تكونين حاملاً أو تخططين لإنجاب طفل، فاستشيري طبيبك للحصول على النصيحة قبل</p><p dir="RTL">تناول هذا الدواء .</p><p dir="RTL">&nbsp;</p><p dir="RTL"><u>الحَمْل</u></p><p dir="RTL"><u>&nbsp;</u></p><p dir="RTL">&bull; لا تتناولي دواء بونفوري خلال الحمل. فإذا استخدمت دواء بونفوري أثناء الحمل، فإن هناك خطر إحداث ضرر على جنينك.</p><p dir="RTL">&bull; لا تستخدميه إذا كنت تحاولين الحمل أو كنت قادرة على الحمل ولا تستخدمين وسيلة منع حمل فعالة.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><u>النساء</u><u> </u><u>القادرات</u><u> </u><u>على</u><u> </u><u>الحمل</u><u>/</u><u>وسائل</u><u> </u><u>منع</u><u> </u><u>الحمل</u><u> </u><u>عند</u><u> </u><u>الإناث</u></p><p dir="RTL"><u>&nbsp;</u></p><p dir="RTL">إذا كنت امرأة قادرة على الحمل :</p><p dir="RTL">&bull; فسيخبرك طبيب ك عن مخاطر حدوث ضرر على جنينك قبل أن تبدئي العلاج باستخدام دواء بونفوري، وينبغي لك إجراء اختبار الحمل</p><p dir="RTL">للتأكد من أن ك لست حاملاً.</p><p dir="RTL">&bull; يجب عليك استخدام وسيلة منع حمل فعالة خلال تناول دواء بونفوري ولمدة أسبوع بعد التوقف عن تناوله.</p><p dir="RTL">&nbsp;</p><p dir="RTL">تحدثي إلى طبيب ك بشأن الوسائل الموثوقة لمنع الحمل .</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا أصبحت حاملاً خلال تناول دواء بونفوري، فتوقفي عن تناوله وأبلغي طبيب ك على الفور.</p><p dir="RTL">إذا أصبحت حاملاً في غضون أسبوع واحد من بعد التوقف عن تناول دواء بونفوري، فتحدثي إلى طبيبك.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><u>الرضاعة</u><u> </u><u>الطبيعية</u></p><p dir="RTL">ينبغي لك الامتناع عن الإرضاع الطبيعي في أثناء تناول دواء بونفوري. وهذا لتجنب خطر إصابة الرضيع بآثار جانبية؛ لأن دواء</p><p dir="RTL">بونفوري قد ينتقل إلى الرضيع من خلال لبن الأم .</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>القيادة</strong><strong> </strong><strong>واستخدام</strong><strong> </strong><strong>الآلات</strong></p><p dir="RTL">من غير المتوقع أن يؤثر دواء بونفوري في قدرتك على القيادة واستخدام الآلات .</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>يحتوي</strong><strong> </strong><strong>دواء</strong><strong> </strong><strong>بونفوري</strong><strong> </strong><strong>على</strong><strong> </strong><strong>اللاكتوز</strong></p><p dir="RTL">يحتوي دواء بونفوري على اللاكتوز، وهو أحد أنواع السكر. إذا كان طبيبك قد أخبرك بأنك تعاني من حساسية مفرطة تجاه بعض السكريات، فتحدث إلى طبيبك قبل تناول هذا الدواء.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>يحتوي</strong><strong> </strong><strong>دواء</strong><strong> </strong><strong>بونفوري</strong><strong> </strong><strong>على</strong><strong> </strong><strong>الصوديوم</strong></p><p dir="RTL">يحتوي هذا الدواء على أقل من ١ ملليمول صوديوم ( ٢٣ مجم) لكل قرص، أي أن الدواء يُعد &quot;خاليًا من الصوديوم&quot; في الأساس.</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">احرص دائمًا على تناول هذا الدواء كيفما أخبرك الطبيب المعالج تمامًا. استشر طبيبك أو الصيدلي إذا لم تكن متأكدًا من كيفية تناوله.</p><p dir="RTL"><strong>كيفية</strong><strong> </strong><strong>التناول</strong></p><p dir="RTL">&bull; ينبغي تناول دواء بونفوري حسب تعليمات الطبيب تمامًا. فلا تغير الجرعة أو تتوقف عن تناوله ما لم يخبرك طبيبك بذلك.</p><p dir="RTL">&bull; تناول قرصا واحدا يوميا. وللمساعدة على تذكيرك بتناول الدواء، ينبغي أن تتناوله في نفس الوقت كل يوم.</p><p dir="RTL">&bull; تناول القرص مع الطعام أو بدون طعام.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>عبوة</strong><strong> </strong><strong>بدء</strong><strong> </strong><strong>العلاج</strong><strong> ( </strong><strong>١٤</strong><strong> </strong><strong>يوما</strong><strong>(</strong></p><p dir="RTL"><strong>&bull; </strong>لا تبدأ علاجك بدواء بونفوري إلا باستخدام عبوة بدء العلاج ، التي ستزداد بها جرعتك تدريجيًّا على مدار ١٤ يومًا. الغرض من مرحلة</p><p dir="RTL">المعايرة هو تقليل أي آثار جانبية ناتجة عن انخفاض معدل ضربات القلب في بداية العلاج.</p><p dir="RTL">&bull; اكتب تاريخ بدء تناول الدواء بجوار اليوم الأول على عبوة بدء العلاج الخاصة بدواء بونفوري.</p><p dir="RTL">&bull; اتبع جدول العلاج التالي الممتد لمدة 14 يومًا.</p><p dir="RTL">&nbsp;</p><table dir="rtl" border="1" cellspacing="0" cellpadding="0"><tbody><tr><td><p dir="RTL"><strong>يوم</strong><strong> </strong><strong>عبوة</strong><strong> </strong><strong>بدء</strong><strong> </strong><strong>العلاج</strong></p></td><td><p dir="RTL"><strong>الجرعة</strong><strong> </strong><strong>اليومية</strong></p><p dir="RTL">&nbsp;</p></td></tr><tr><td><p dir="RTL">اليوم ١</p></td><td><p dir="RTL">٢ مجم</p></td></tr><tr><td><p dir="RTL">اليوم ٢</p></td><td><p dir="RTL">٢ مجم</p></td></tr><tr><td><p dir="RTL">اليوم ٣</p></td><td><p dir="RTL">٣ مجم</p></td></tr><tr><td><p dir="RTL">اليوم ٤</p></td><td><p dir="RTL">٣ مجم</p></td></tr><tr><td><p dir="RTL">اليوم ٥</p></td><td><p dir="RTL">٤ مجم</p></td></tr><tr><td><p dir="RTL">اليوم ٦</p></td><td><p dir="RTL">٤ مجم</p></td></tr><tr><td><p dir="RTL">اليوم ٧</p></td><td><p dir="RTL">٥ مجم</p></td></tr><tr><td><p dir="RTL">اليوم ٨</p></td><td><p dir="RTL">٦ مجم</p></td></tr><tr><td><p dir="RTL">اليوم ٩</p></td><td><p dir="RTL">٧ مجم</p></td></tr><tr><td><p dir="RTL">اليوم ١٠</p></td><td><p dir="RTL">٨ مجم</p></td></tr><tr><td><p dir="RTL">اليوم ١١</p></td><td><p dir="RTL">٩ مجم</p></td></tr><tr><td><p dir="RTL">اليوم ١٢</p></td><td><p dir="RTL">١٠ مجم</p></td></tr><tr><td><p dir="RTL">اليوم ١٣</p></td><td><p dir="RTL">١٠ مجم</p></td></tr><tr><td><p dir="RTL">اليوم ١٤</p></td><td><p dir="RTL">١٠ مجم</p></td></tr></tbody></table><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>جرعة</strong><strong> </strong><strong>المداومة</strong></p><p dir="RTL">&bull; <strong>بعد</strong> الانتهاء من تناول الأقراص في عبوة بدء العلاج، استمر على العلاج بجرعة مداومة تركيزها ٢٠ مجم.</p><p dir="RTL"><strong>&bull; </strong>اكتب تاريخ بدء تناول جرعة المداومة التي تركيزها ٢٠ مجم بجوار الأسبوع الأول من عبوة تغليف البليستر لدواء بونفوري التي بتركيز٢٠ مجم .</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>ما</strong><strong> </strong><strong>ينبغي</strong><strong> </strong><strong>عليك</strong><strong> </strong><strong>فعله</strong><strong> </strong><strong>إذا</strong><strong> </strong><strong>تناولت</strong><strong> </strong><strong>جرعة</strong><strong> </strong><strong>زائدة</strong><strong> </strong><strong>من</strong><strong> </strong><strong>دواء</strong><strong> </strong><strong>بونفوري</strong></p><p dir="RTL">في حالة تناولك دواء بونفوري أكثر مما ينبغي، اتصل بطبيبك على الفور أو اذهب مباشرة إلى المستشفى. اصطحب عبوة الدواء ونشرة العبوة هذه معك.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>في</strong><strong> </strong><strong>حالة</strong><strong> </strong><strong>نسيان</strong><strong> </strong><strong>تناول</strong><strong> </strong><strong>دواء</strong><strong> </strong><strong>بونفوري</strong></p><p dir="RTL">لا تتناول جرعة مضاعفة لتعويض جرعة فائتة.</p><p dir="RTL">&bull; إذا فاتك تناول ما يصل إلى ٣ أقراص على التوالي من دواء بونفوري خلال تناول جرعة بدء العلاج أو جرعة المداومة، فيمكنك مواصلة العلاج بتناول <strong>أول</strong><strong> </strong>جرعة فاتتك. خذ <strong>قرصا</strong><strong> </strong><strong>واحدا</strong><strong> </strong>بمجرد أن تتذكر، ثم تناول قرصًا واحدًا يوميًا لمواصلة تناول جرعة بدء العلاج أو جرعة المداومة على النحو المخطط له.</p><p dir="RTL">&bull; إذا فاتك تناول ٤ أقراص من دواء بونفوري أو أكثر على التوالي خلال تناول جرعة بدء العلاج أو جرعة المداومة، فأنت بحاجة إلى إعادة العلاج باستخدام عبوة أخرى من عبوات بدء العلاج مدتها ١٤ يومًا. اتصل بطبيبك على الفور إذا فاتتك ٤ جرعات أو أكثر من دواء</p><p dir="RTL">بونفوري.</p><p dir="RTL">&nbsp;</p><p dir="RTL">اكتب تاريخ بدء تناول الدواء، حتى تعرف ما إذا فاتك تناول ٤ جرعات أو أكثر على التوالي.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>لا</strong><strong> </strong><strong>تتوقف</strong><strong> </strong><strong>عن</strong><strong> </strong><strong>تناول</strong><strong> </strong><strong>دواء</strong><strong> </strong><strong>بونفوري</strong><strong> </strong><strong>دون</strong><strong> </strong><strong>التحدث</strong><strong> </strong><strong>إلى</strong><strong> </strong><strong>طبيبك</strong><strong> </strong><strong>أولا</strong><strong> .</strong></p><p dir="RTL">لا تستأنف دواء بونفوري بعد إيقافه لمدة 4 أيام أو أكثر على التوالي دون طلب المشورة من طبيبك. سوف تحتاج إلى استئناف العلاج باستخدام عبوة جديدة لبدء العلاج.</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا كانت لديك المزيد من الأسئلة حول استخدام هذا الدواء، فتوجه بها إلى طبيبك المعالج أو الصيدلي.</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">مثل جميع الأدوية، يمكن أن يُسبب هذا الدواء آثارًا جانبية، على الرغم من عدم إصابة الجميع بها.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><u>قد</u><u> </u><u>تتسم</u><u> </u><u>بعض</u><u> </u><u>الآثار</u><u> </u><u>الجانبية</u><u> </u><strong><u>بالخطورة</u></strong><strong><u> </u></strong><u>أو</u><u> </u><u>تصبح</u><u> </u><u>خطيرة</u></p><p dir="RTL">&nbsp;</p><p dir="RTL">أخبر طبيبك أو الصيدلي فورًا إذا لاحظت أيًا من الآثار الجانبية المذكورة أدناه لأنها قد تكون علامات على آثار خطيرة :</p><p dir="RTL"><strong>آثار</strong><strong> </strong><strong>شائعة</strong><strong> </strong>(قد تؤثر على ما يصل إلى ١ من بين ١٠ أشخاص(</p><p dir="RTL">&bull; عدوى المسالك البولية</p><p dir="RTL">&bull; التهاب الشعب الهوائية</p><p dir="RTL">&bull; البرد (الإنفلونزا(</p><p dir="RTL">&bull; عدوى فيروسية في الأنف، أو الحلق، أو الصدر(عدوى فيروسية في الجهاز التنفسي(</p><p dir="RTL">&bull; عدوى فيروسية</p><p dir="RTL">&bull; عدوى فيروس الهربس النطاقي (القوباء المنطقية(</p><p dir="RTL">&bull; عدوى الرئة (الالتهاب الرئوي(</p><p dir="RTL">&bull; الإحساس بعدم الاتزان (لدوار(</p><p dir="RTL">&bull; حمى (سخونة(</p><p dir="RTL">&bull; تراكم السوائل في الجزء الخلفي من العين (الشبكية) قد يسبب تغيرات في الرؤية تشمل فقدان البصر (الوذمة البقعية(</p><p dir="RTL">&bull; تشنجات (نوبات صرع(</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>آثار</strong><strong> </strong><strong>جانبية</strong><strong> </strong><strong>غير</strong><strong> </strong><strong>شائعة</strong><strong> </strong>(تصيب ما يصل إلى ١ من بين ١٠٠ شخص(</p><p dir="RTL">&bull; انخفاض ضربات القلب (تباطوء ضربات القلب(</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL"><u>الآثار</u><u> </u><u>الجانبية</u><u> </u><u>الأخرى</u></p><p dir="RTL"><u>&nbsp;</u></p><p dir="RTL"><strong>آثار</strong><strong> </strong><strong>شائعة</strong><strong>&nbsp; جدا </strong>(قد تصيب أكثر من ١ من بين ١٠ أشخاص (</p><p dir="RTL">&bull; عدوى الأنف، أو الجيوب الأنفية، أو الحلق (التهاب البلعوم الأنفي، عدوى الجهاز التنفسي(</p><p dir="RTL">&bull; زيادة مستوى إنزيمات الكبد في الدم (علامة على وجود مشكلات في الكبد (</p><p dir="RTL">&bull; انخفاض عدد أحد أنواع خلايا الدم البيضاء، يسمى الخلايا الليمفاوية (قلة الليمفاويات(</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>آثار</strong><strong> </strong><strong>شائعة</strong><strong> </strong>(قد تؤثر على ما يصل إلى ١ من بين ١٠ أشخاص(</p><p dir="RTL">&bull; ارتفاع ضغط الدم</p><p dir="RTL">&bull; ألم في الظهر.</p><p dir="RTL">&bull; الشعور بالتعب الشديد (الإرهاق(</p><p dir="RTL">&bull; الشعور بالدوخة</p><p dir="RTL">&bull; ضيق في التنفس (صعوبة في التنفس(</p><p dir="RTL">&bull; ارتفاع مستوى الكوليسترول في الدم (فرط كوليسترول الدم(</p><p dir="RTL">&bull; ألم المفاصل</p><p dir="RTL">&bull; ألم في الذراع أو الساق</p><p dir="RTL">&bull; اكتئاب</p><p dir="RTL">&bull; صعوبة النوم (الأرق(</p><p dir="RTL">&bull; السعال</p><p dir="RTL">&bull; حكة، أو سيلان الأنف أو انسدادها (التهاب الأنف)، التهاب الحلق أو تهيجه (التهاب البلعوم، التهاب الحنجرة)، عدوى الجيوب الأنفية (التهاب الجيوب الأنفية)</p><p dir="RTL">&bull; الشعور بالقلق (التوتر)</p><p dir="RTL">&bull; انخفاض الشعور أو الإحساس، وخاصة في الجلد (نقص الإحساس)</p><p dir="RTL">&bull; زيادة مستوى البروتين في الدم قد يشير إلى وجود عدوى أو التهاب (زيادة بروتين سي التفاعلي)</p><p dir="RTL">&bull; الشعور بالنعاس</p><p dir="RTL">&bull; عسر الهضم</p><p dir="RTL">&bull; تورم اليدين أو الكاحلين أو القدمين (وذمة طرفية)</p><p dir="RTL">&bull; الصداع النصفي</p><p dir="RTL">&bull; التواء الأربطة</p><p dir="RTL">&bull; ضيق في الصدر</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>آثار</strong><strong> </strong><strong>جانبية</strong><strong> </strong><strong>غير</strong><strong> </strong><strong>شائعة</strong><strong> </strong>(تصيب ما يصل إلى ١ من بين ١٠٠ شخص)</p><p dir="RTL">&bull; ارتفاع مستوى البوتاسيوم في الدم (فرط بوتاسيوم الدم)</p><p dir="RTL">&bull; تورم المفصل</p><p dir="RTL">&bull; جفاف الفم</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الإبلاغ</strong><strong> </strong><strong>عن</strong><strong> </strong><strong>الآثار</strong><strong> </strong><strong>الجانبية</strong></p><p dir="RTL">إذا تعرضت لأي آثار جانبية ، فتحدث إلى طبيبك أو الصيدلي أو الممرضة .ويتضمن ذلك أي آثار جانبية محتملة غير مُدرجة في هذه النشرة. من خلال الإبلاغ عن الآثار الجانبية يمكن أن تساعد على توفير مزيد من المعلومات حول سلامة هذا الدواء.</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">&nbsp;</p><p dir="RTL">احفظ هذا الدواء بعيدًا عن مرأى الأطفال ومتناولهم.</p><p dir="RTL">يشير تاريخ انتهاء الصلاحية EXP على العلبة الكرتونية والبليستر. لا يجوز استعمال هذا الدواء بعد تاريخ انتهاء الصلاحية المدون بعد حروف إلى اليوم الأخير من الشهر المحدد.</p><p dir="RTL">&nbsp;</p><p dir="RTL">لا يُحفظ في درجة حرارة أعلى من ٣٠ درجة مئوية</p><p dir="RTL">&nbsp;</p><p dir="RTL">لا تتخلص من أي دواء بإلقائه في مياه الصرف أو فضلات المنزل. اسأل الصيدلي عن كيفية التخلص من الأدوية التي لم تعد بحاجة إلى استخدامها. ستساعد هذه الإجراءات على حماية البيئة.</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>ما</strong><strong> </strong><strong>يحتويه</strong><strong> </strong><strong>دواء</strong><strong> </strong><strong>بونفوري</strong></p><p dir="RTL">&bull; المادة الفعالة هي بونيسيمود</p><p dir="RTL">&bull; السواغات الأخرى هي:</p><p dir="RTL"><u>لُب</u><u> </u><u>القرص</u></p><p dir="RTL">كروس كارميلوز الصوديوم، لاكتوز أحادي الإماهة (انظر &quot;يحتوي دواء بونفوري على اللاكتوز&quot;)، سترات الماغنسيوم، سيليلوز بلوري</p><p dir="RTL">مكرويِّ ، بوفيدون 30 K، السيليكا اللامائية الغروانية، لوريل سلفات الصوديوم.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><u>غلاف</u><u> </u><u>القرص</u></p><p dir="RTL">&nbsp;</p><p dir="RTL">هيبروميلوز ٢٩١٠ ، لاكتوز أحادي الإماهة، ماكروجول ٣٣٥٠ ، ثاني أكسيد التيتانيوم، ثلاثي الأستين.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><em>أقراص</em><em> </em><em>بونفوري</em><em> </em><em>بتركيز</em><em> </em><em>٣</em><em> </em><em>مجم</em><em> </em><em>مغلفة</em><em> </em><em>بطبقة</em><em> </em><em>رقيقة</em></p><p dir="RTL">أكسيد الحديد الأحمر E172) ( وأكسيد الحديد الأصفر E172) (</p><p dir="RTL">&nbsp;</p><p dir="RTL"><em>أقراص</em><em> </em><em>بونفوري</em><em> </em><em>بتركيز</em><em> </em><em>٤</em><em> </em><em>مجم</em><em> </em><em>مغلفة</em><em> </em><em>بطبقة</em><em> </em><em>رقيقة</em></p><p dir="RTL">أكسيد الحديد الأحمر E172) &nbsp;(وأكسيد الحديد الأسود E172) )</p><p dir="RTL">&nbsp;</p><p dir="RTL"><em>أقراص</em><em> </em><em>بونفوري</em><em> </em><em>بتركيز</em><em> </em><em>٥</em><em> </em><em>مجم</em><em> </em><em>مغلفة</em><em> </em><em>بطبقة</em><em> </em><em>رقيقة</em></p><p dir="RTL">أكسيد الحديد الأسود E172) &nbsp;(وأكسيد الحديد الأصفر E172) (</p><p dir="RTL">&nbsp;</p><p dir="RTL"><em>أقراص</em><em> </em><em>بونفوري</em><em> </em><em>بتركيز</em><em> </em><em>٧</em><em> </em><em>مجم</em><em> </em><em>مغلفة</em><em> </em><em>بطبقة</em><em> </em><em>رقيقة</em></p><p dir="RTL">أكسيد الحديد الأحمر E172) ( &nbsp;وأكسيد الحديد الأصفر E172) (</p><p dir="RTL">&nbsp;</p><p dir="RTL"><em>أقراص</em><em> </em><em>بونفوري</em><em> </em><em>بتركيز</em><em> </em><em>٨</em><em> </em><em>مجم</em><em> </em><em>مغلفة</em><em> </em><em>بطبقة</em><em> </em><em>رقيقة</em></p><p dir="RTL">أكسيد الحديد الأحمر E172) ( &nbsp;وأكسيد الحديد الأسود E172) (</p><p dir="RTL">&nbsp;</p><p dir="RTL"><em>أقراص</em><em> </em><em>بونفوري</em><em> </em><em>بتركيز</em><em> </em><em>٩</em><em> </em><em>مجم</em><em> </em><em>مغلفة</em><em> </em><em>بطبقة</em><em> </em><em>رقيقة</em></p><p dir="RTL">أكسيد الحديد الأحمر E172) ( &nbsp;وأكسيد الحديد الأسود E172) ( &nbsp;وأكسيد الحديد الأصفر E172) (</p><p dir="RTL">&nbsp;</p><p dir="RTL"><em>أقراص</em><em> </em><em>بونفوري</em><em> </em><em>بتركيز</em><em> </em><em>١٠</em><em> </em><em>مجم</em><em> </em><em>مغلفة</em><em> </em><em>بطبقة</em><em> </em><em>رقيقة</em></p><p dir="RTL">أكسيد الحديد الأحمر E172) ( &nbsp;وأكسيد الحديد الأصفر E172) (</p><p dir="RTL">&nbsp;</p><p dir="RTL"><em>أقراص</em><em> </em><em>بونفوري</em><em> </em><em>بتركيز</em><em> </em><em>٢٠</em><em> </em><em>مجم</em><em> </em><em>مغلفة</em><em> </em><em>بطبقة</em><em> </em><em>رقيقة</em></p><p dir="RTL">أكسيد الحديد الأصفر E172) (</p><p dir="RTL"><strong>&nbsp;</strong></p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>شكل</strong><strong> </strong><strong>دواء</strong><strong> </strong><strong>بونفوري</strong><strong> </strong><strong>ومحتويات</strong><strong> </strong><strong>العبوة</strong></p><p dir="RTL">أقراص بونفوري بتركيز ٢ مجم المغلفة بطبقة رقيقة عبارة عن أقراص بيضاء، مستديرة، محدبة الجانبين، مغلفة بطبقة رقيقة وقطرها ٥ ملم مع وجود الرقم &quot; ٢&quot; على أحد الجانبين وقوس على الجانب الآخر.</p><p dir="RTL">&nbsp;</p><p dir="RTL">أقراص بونفوري ٣ مجم المغلفة بطبقة رقيقة عبارة عن أقراص حمراء، مستديرة، محدبة الجانبين، مغلفة بطبقة رقيقة وقطرها ٥ ملم مع وجود الرقم &quot; ٣ &quot; على أحد الجانبين وقوس على الجانب الآخر.</p><p dir="RTL">&nbsp;</p><p dir="RTL">أقراص بونفوري ٤ مجم المغلفة بطبقة رقيقة عبارة عن أقراص أرجوانية، مستديرة، محدبة الجانبين، مغلفة بطبقة رقيقة وقطرها ٥ ملم مع وجود الرقم &quot; ٤&quot; على أحد الجانبين وقوس على الجانب الآخر.</p><p dir="RTL">&nbsp;</p><p dir="RTL">أقراص بونفوري بتركيز ٥ مجم المغلفة بطبقة رقيقة عبارة عن أقراص خضراء، مستديرة، محدبة الجانبين، مغلفة بطبقة رقيقة وقطرها ٨٬٦ ملم. مع وجود الرقم &quot; ٥&quot; على أحد الجانبين، وقوس وحرف &quot;A&quot; على الجانب الآخر</p><p dir="RTL">&nbsp;</p><p dir="RTL">أقراص بونفوري بتركيز ٦ مجم المغلفة بطبقة رقيقة عبارة عن أقراص بيضاء، مستديرة، محدبة الجانبين، مغلفة بطبقة رقيقة وقطرها ٨٬٦ ملم مع وجود الرقم &quot; <u>٦</u>&quot; على أحد الجانبين، وقوس وحرف على الجانب الآخر. &quot;A&quot;</p><p dir="RTL">&nbsp;</p><p dir="RTL">أقراص بونفوري ٧ مجم المغلفة بطبقة رقيقة عبارة عن أقراص حمراء، مستديرة، محدبة الجانبين، مغلفة بطبقة رقيقة وقطرها ٨٬٦ ملم مع وجود الرقم &quot; ٧&quot; على أحد الجانبين، وقوس وحرف على الجانب الآخر. &quot;A&quot;</p><p dir="RTL">&nbsp;</p><p dir="RTL">أقراص بونفوري بتركيز ٨ مجم المغلفة بطبقة رقيقة عبارة عن أقراص أرجوانية، مستديرة، محدبة الجانبين، مغلفة بطبقة رقيقة وقطرها ٨٬٦ ملم مع وجود الرقم &quot; ٨&quot; على أحد الجانبين، وقوس وحرف على الجانب الآخر. &quot;A&quot;</p><p dir="RTL">&nbsp;</p><p dir="RTL">أقراص بونفوري بتركيز ٩ مجم المغلفة بطبقة رقيقة عبارة عن أقراص بنية، مستديرة، محدبة الجانبين، مغلفة بطبقة رقيقة وقطرها ٨٬٦ ملم مع وجود الرقم &quot; <u>٩</u>&quot; على أحد الجانبين، وقوس وحرف على الجانب الآخر. &quot;A&quot;</p><p dir="RTL">&nbsp;</p><p dir="RTL">أقراص بونفوري ١٠ مجم المغلفة بطبقة رقيقة عبارة عن أقراص برتقالية، مستديرة، محدبة الجانبين، مغلفة بطبقة رقيقة وقطرها ٨٬٦ ملم مع وجود الرقم &quot; ١٠ &quot; على أحد الجانبين، وقوس وحرف على الجانب الآخر. &quot;A&quot;</p><p dir="RTL">&nbsp;</p><p dir="RTL">أقراص بونفوري بتركيز ٢٠ مجم المغلفة بطبقة رقيقة عبارة عن أقراص صفراء، مستديرة، محدبة الجانبين، مغلفة بطبقة رقيقة وقطرها ٨٬٦ ملم مع وجود الرقم &quot; ٢٠ &quot; على أحد الجانبين، وقوس وحرف على الجانب الآخر. &quot;A&quot;</p><p dir="RTL">&nbsp;</p><p dir="RTL"><u>عبوة</u><u> </u><u>دواء</u><u> </u><u>بونفوري</u><u> </u><u>لبدء</u><u> </u><u>العلاج</u> (شكل محفظة(</p><p dir="RTL">&nbsp;</p><p dir="RTL">تحتوي كل عبوة بتغليف بليستر فيها ١٤ قرصًا مغلفًا بطبقة رقيقة لجدول علاجي مدته أسبوعان على:</p><p dir="RTL">قرصين مغلفين بطبقة رقيقة بتركيز ٢ مجم</p><p dir="RTL">قرصين مغلفين بطبقة رقيقة بتركيز ٣ مجم</p><p dir="RTL">قرصين مغلفين بطبقة رقيقة بتركيز ٤ مجم</p><p dir="RTL">قرص واحد مغلف بطبقة رقيقة بتركيز ٥ مجم</p><p dir="RTL">قرص واحد مغلف بطبقة رقيقة بتركيز ٦ مجم</p><p dir="RTL">قرص واحد مغلف بطبقة رقيقة بتركيز ٧ مجم</p><p dir="RTL">قرص واحد مغلف بطبقة رقيقة بتركيز ٨ مجم</p><p dir="RTL">قرص واحد مغلف بطبقة رقيقة بتركيز ٩ مجم</p><p dir="RTL">3 أقراص مغلفة بطبقة رقيقة بتركيز ١٠ مجم</p><p dir="RTL">&nbsp;</p><p dir="RTL"><u>أقراص</u><u> </u><u>بونفوري</u><u> </u><u>بتركيز</u><u> </u><u>٢٠</u><u> </u><u>مجم</u><u> </u><u>مغلفة</u><u> </u><u>بطبقة</u><u> </u><u>رقيقة</u><u> (</u><u>عبوة</u><u> </u><u>المداومة) </u><u>(</u><u>شكل</u><u> </u><u>محفظة</u><u>(</u></p><p dir="RTL">&nbsp;</p><p dir="RTL">كل عبوة بتغليف بليستر فيها ٢٨ قرصًا مغلفًا بطبقة رقيقة لجدول علاجي مدته ٤ أسابيع.</p><p dir="RTL">&nbsp;</p><p dir="RTL">قد لا تُطرح جميع أحجام العبوات في الأسواق.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>للتواصل</strong><strong> </strong><strong>معنا،</strong><strong> </strong><strong>تفضل</strong><strong> </strong><strong>بزيارة</strong> www.janssen.com/contact-us</p><p dir="RTL"><strong>&nbsp;</strong></p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>حامل</strong><strong> </strong><strong>الرخصة</strong><strong> </strong><strong>التسويقية</strong></p><p dir="RTL">جانسن سيلاج انترناشونال ان فى, ترنهوتسويج- ٣٠ , بي- ٢٣٤٠ بيرس- بلجيكا</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>الشركة</strong><strong> </strong><strong>المصنّعة</strong></p><p dir="RTL">باثيون فرنسا، ٤٠ بوليفراد دو شامبريه ٣٨٣٠٠ بورجيون جالليلو، فرنسا</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            آخر مراجعة لهذه النشرة كان في 5 يوليو 2023
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Ponvory 2 mg film-coated tablets 
Ponvory 3 mg film-coated tablets 
Ponvory 4 mg film-coated tablets 
Ponvory 5 mg film-coated tablets 
Ponvory 6 mg film-coated tablets 
Ponvory 7 mg film-coated tablets 
Ponvory 8 mg film-coated tablets 
Ponvory 9 mg film-coated tablets 
Ponvory 10 mg film-coated tablets 
Ponvory 20 mg film-coated tablets

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Ponvory 2 mg film-coated tablets

Each film-coated tablet contains 2 mg of ponesimod

Excipient with known effect
Each tablet contains 23 mg of lactose. Ponvory 3 mg film-coated tablets
Each film-coated tablet contains 3 mg of ponesimod

Excipient with known effect
Each tablet contains 22 mg of lactose. Ponvory 4 mg film-coated tablets
Each film-coated tablet contains 4 mg of ponesimod

Excipient with known effect
Each tablet contains 21 mg of lactose. Ponvory 5 mg film-coated tablets
Each film-coated tablet contains 5 mg of ponesimod

Excipient with known effect
Each tablet contains 118 mg of lactose. Ponvory 6 mg film-coated tablets
Each film-coated tablet contains 6 mg of ponesimod

Excipient with known effect
Each tablet contains 117 mg of lactose.
 
Ponvory 7 mg film-coated tablets

Each film-coated tablet contains 7 mg of ponesimod

Excipient with known effect
Each tablet contains 117 mg of lactose. Ponvory 8 mg film-coated tablets
Each film-coated tablet contains 8 mg of ponesimod

Excipient with known effect
Each tablet contains 116 mg of lactose. Ponvory 9 mg film-coated tablets
Each film-coated tablet contains 9 mg of ponesimod

Excipient with known effect
Each tablet contains 115 mg of lactose. Ponvory 10 mg film-coated tablets
Each film-coated tablet contains 10 mg of ponesimod

Excipient with known effect
Each tablet contains 114 mg of lactose. Ponvory 20 mg film-coated tablets
Each film-coated tablet contains 20 mg of ponesimod

Excipient with known effect
Each tablet contains 104 mg of lactose.

For the full list of excipients, see section 6.1.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Film-coated tablet (tablet) Ponvory 2 mg film-coated tablets
White, round, biconvex, film-coated tablet of 5 mm diameter with “2” on one side and an arch on the other side.

Ponvory 3 mg film-coated tablets

Red, round, biconvex, film-coated tablet of 5 mm diameter with “3” on one side and an arch on the other side.

Ponvory 4 mg film-coated tablets

Purple, round, biconvex, film-coated tablet of 5 mm diameter with “4” on one side and an arch on the other side.
 
Ponvory 5 mg film-coated tablets

Green, round, biconvex, film-coated tablet of 8.6 mm diameter with “5” on one side and an arch and an “A” on the other side.

Ponvory 6 mg film-coated tablets

White, round, biconvex, film-coated tablet of 8.6 mm diameter with “6” on one side and an arch and an “A” on the other side.

Ponvory 7 mg film-coated tablets

Red, round, biconvex, film-coated tablet of 8.6 mm diameter with “7” on one side and an arch and an “A” on the other side.

Ponvory 8 mg film-coated tablets

Purple, round, biconvex, film-coated tablet of 8.6 mm diameter with “8” on one side and an arch and an “A” on the other side.

Ponvory 9 mg film-coated tablets

Brown, round, biconvex, film-coated tablet of 8.6 mm diameter with “9” on one side and an arch and an “A” on the other side.

Ponvory 10 mg film-coated tablets

Orange, round, biconvex, film-coated tablet of 8.6 mm diameter with “10” on one side and an arch and an “A” on the other side.

Ponvory 20 mg film-coated tablets

Yellow, round, biconvex, film-coated tablet of 8.6 mm diameter with “20” on one side and an arch and an “A” on the other side.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Ponvory is indicated for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS) with active disease defined by clinical or imaging features.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Treatment should be initiated under the supervision of a physician experienced in the management of multiple sclerosis.</p><p>&nbsp;</p><p><u>Posology</u></p><p>&nbsp;</p><p><em>Treatment initiation</em></p><p>Treatment must be started with the 14-day treatment initiation pack (see section 6.5). Treatment starts with one 2 mg tablet orally once daily on day 1 and dose-escalation progresses with the titration schedule outlined in Table 1.</p><p>&nbsp;</p><p>Table 1: Dose titration regimen</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>Titration day</strong></p></td><td style="vertical-align:top"><p><strong>Daily dose</strong></p></td></tr><tr><td style="vertical-align:top"><p>Day 1 and 2</p></td><td style="vertical-align:top"><p>2 mg</p></td></tr><tr><td style="vertical-align:top"><p>Day 3 and 4</p></td><td style="vertical-align:top"><p>3 mg</p></td></tr><tr><td style="vertical-align:top"><p>Day 5 and 6</p></td><td style="vertical-align:top"><p>4 mg</p></td></tr><tr><td style="vertical-align:top"><p>Day 7</p></td><td style="vertical-align:top"><p>5 mg</p></td></tr><tr><td style="vertical-align:top"><p>Day 8</p></td><td style="vertical-align:top"><p>6 mg</p></td></tr><tr><td style="vertical-align:top"><p>Day 9</p></td><td style="vertical-align:top"><p>7 mg</p></td></tr><tr><td style="vertical-align:top"><p>Day 10</p></td><td style="vertical-align:top"><p>8 mg</p></td></tr><tr><td style="vertical-align:top"><p>Day 11</p></td><td style="vertical-align:top"><p>9 mg</p></td></tr><tr><td style="vertical-align:top"><p>Day 12, 13 and 14</p></td><td style="vertical-align:top"><p>10 mg</p></td></tr></tbody></table><p><strong>&nbsp;</strong></p><p>If dose titration is interrupted, missed dose instructions must be followed (see also section 4.2, &ldquo;Re-initiation of therapy following treatment interruption during dose titration or maintenance period&rdquo;).</p><p>&nbsp;</p><p><em>Maintenance dose</em></p><p>After dose titration is complete (see also section 4.2, Treatment initiation)<em>, </em>the recommended maintenance dose of Ponvory is one 20 mg tablet taken orally once daily.</p><p>&nbsp;</p><p><em>Re-initiation of therapy following treatment interruption during dose titration or maintenance period</em></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if less than 4 consecutive doses are missed, resume treatment with the first missed dose.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if 4 or more consecutive doses are missed, reinitiate treatment with day 1 (2 mg) of the titration regimen (new treatment initiation pack).</p><p>&nbsp;</p><p>The same first dose monitoring as for treatment initiation is recommended when 4 or more consecutive doses of ponesimod are missed during the titration or maintenance periods.</p><p>&nbsp;</p><p><u>Special populations</u></p><p>&nbsp;</p><p><em>Elderly population</em></p><p>Clinical studies of ponesimod did not include patients aged 65 years and older. Ponesimod should be prescribed with caution in patients aged 65 years and over due to the lack of data on safety and efficacy.</p><p>&nbsp;</p><p><em>Renal impairment</em></p><p>Based on clinical pharmacology studies, no dose adjustment is needed in patients with mild to severe renal impairment (see section 5.2).</p><p>&nbsp;</p><p><em>Hepatic impairment</em></p><p>No dose adjustment is necessary in patients with mild hepatic impairment (Child-Pugh class A) (see section 5.2).</p><p>&nbsp;</p><p>Ponvory is contraindicated in patients with moderate or severe hepatic impairment (Child-Pugh class B and C, respectively) (see sections 4.3, 5.2).</p><p>&nbsp;</p><p><em>Paediatric population</em></p><p>The safety and efficacy of Ponvory in children and adolescents aged less than 18 years have not been established. No data are available.</p><p>&nbsp;</p><p><u>Method of administration</u></p><p>&nbsp;</p><p>Ponesimod should be administered orally once daily. Ponesimod can be taken with or without food (see section 5.2).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                -	Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.
-	Immunodeficient state (see section 4.4).
-	Patients who in the last 6 months experienced myocardial infarction, unstable angina, stroke, transient ischaemic attack (TIA), decompensated heart failure requiring hospitalisation, or New York Heart Association (NYHA) Class III or IV heart failure.
-	Patients who have presence of Mobitz type II second-degree, third-degree atrioventricular (AV) block, or sick sinus syndrome, unless patient has a functioning pacemaker (see section 4.4).
-	Severe active infections, active chronic infections.
-	Active malignancies.
-	Moderate or severe hepatic impairment (Child-Pugh class B and C, respectively).
-	During pregnancy and in women of childbearing potential not using effective contraception (see section 4.6).

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Bradyarrhythmia</u></p><p>&nbsp;</p><p><em>Initiation of treatment with ponesimod</em></p><p>Prior to treatment initiation with ponesimod, an electrocardiogram (ECG) in all patients should be obtained to determine whether pre-existing conduction abnormalities are present. In patients with certain pre-existing conditions, first-dose monitoring is recommended (see below).</p><p>&nbsp;</p><p>Initiation of ponesimod treatment may result in a transient decrease in heart rate (HR) and AV conduction delays (see sections 4.8 and 5.1), therefore an up-titration scheme must be used to reach the maintenance dose of ponesimod (20 mg) (see section 4.2).</p><p>&nbsp;</p><p>After the first dose of ponesimod, the decrease in HR typically begins within an hour and reaches its nadir within 2-4 hours. The HR typically recovers to baseline levels 4-5 hours after administration. The mean decrease in HR on day 1 of dosing (2 mg) was 6 bpm. With up-titration after day 1, the decrease in HR is less pronounced with no further post-dose decrease in HR observed after day 3.</p><p>&nbsp;</p><p>Caution should be applied when ponesimod is initiated in patients receiving treatment with a beta-blocker because of the additive effects on lowering heart rate; temporary interruption of the beta-blocker treatment may be needed prior to initiation of ponesimod (see section below and section 4.5).</p><p>&nbsp;</p><p>For patients receiving a stable dose of a beta-blocker, the resting HR should be considered before introducing ponesimod treatment. If the resting HR is greater than 55 bpm under chronic beta-blocker treatment, ponesimod can be introduced. If resting HR is less than or equal to 55 bpm, beta-blocker treatment should be interrupted until the baseline HR is greater than 55 bpm. Treatment with ponesimod can then be initiated and treatment with a beta-blocker can be reinitiated after ponesimod has been up-titrated to the target maintenance dose (see section 4.5). Beta-blocker treatment can be initiated in patients receiving stable doses of ponesimod.</p><p>&nbsp;</p><p><em>First dose monitoring in patients with certain pre-existing cardiac conditions</em></p><p>Because initiation of ponesimod treatment may result in a decrease in HR, first-dose 4-hour monitoring is recommended for patients with sinus bradycardia [HR less than 55 beats per minute (bpm)], first- or second-degree [Mobitz type I] AV block, or a history of myocardial infarction or heart failure occurring more than 6 months prior to treatment initiation and in stable condition (see</p><p>section 5.1).</p><p>&nbsp;</p><p>Administer the first dose of ponesimod in a setting where resources to appropriately manage symptomatic bradycardia are available. Monitor patients for 4 hours after the first dose for signs and symptoms of bradycardia with a minimum of hourly pulse and blood pressure measurements. Obtain an ECG in these patients at the end of the 4-hour observation period.</p><p>&nbsp;</p><p>Additional monitoring after 4-hours is recommended if any of the following abnormalities are present (even in the absence of symptoms), continue monitoring until the abnormality resolves:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; HR 4 hours postdose is less than 45 bpm</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; HR 4 hours postdose is at the lowest value postdose, suggesting that the maximum pharmacodynamic effect on the heart may not have occurred</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The ECG 4 hours postdose shows new onset second-degree or higher AV block</p><p>&nbsp;</p><p>If postdose symptomatic bradycardia, bradyarrhythmia, or conduction related symptoms occur, or if ECG 4 hours post-dose shows new onset second degree or higher AV block or QTc greater than or equal to 500 msec, initiate appropriate management, begin continuous ECG monitoring, and continue monitoring until the symptoms have resolved if no pharmacological treatment is required. If pharmacological treatment is required, continue monitoring overnight and repeat 4-hour monitoring after the second dose.</p><p>&nbsp;</p><p><em>Cardiologist advice should be obtained before initiation of ponesimod in the following patients to determine overall benefit risk and the most appropriate monitoring strategy</em></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; In patients with significant QT prolongation (QTc greater than 500 msec) or who are already being treated with QT-prolonging medicinal products with known arrhythmogenic properties (risk of torsades de pointes)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; In patients with atrial flutter/fibrillation or arrhythmias treated with Class Ia (e.g., quinidine, procainamide) or Class III (e.g., amiodarone, sotalol) anti-arrhythmic medicinal products (see section 4.5)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; In patients with unstable ischaemic heart disease, cardiac decompensated failure occurring more than 6 months prior to treatment initiation, history of cardiac arrest, cerebrovascular disease (TIA, stroke occurring more than 6 months prior to treatment initiation), and uncontrolled hypertension, since significant bradycardia may be poorly tolerated in these patients, treatment is not recommended</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; In patients with a history of Mobitz Type II second degree AV block or higher-grade AV block, sick-sinus syndrome, or sino-atrial heart block (see section 4.3)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; In patients with a history of recurrent syncope or symptomatic bradycardia</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; In patients receiving concurrent therapy with drugs that decrease heart rate (e.g., beta-blockers, non-dihydropyridine calcium channel blockers - diltiazem and verapamil, and other drugs that may decrease HR such as digoxin) (see above and section 4.5), consider potential need to switch to non-HR lowering medicinal products. Concomitant use of these medicinal products during ponesimod initiation may be associated with severe bradycardia and heart block.</p><p>&nbsp;</p><p><u>Infections</u></p><p>&nbsp;</p><p><em>Risk of infections</em></p><p>Ponesimod causes a dose-dependent reduction in peripheral lymphocyte count to 30-40% of baseline values due to reversible sequestration of lymphocytes in lymphoid tissues. Ponesimod may therefore increase the risk of infections (see section 4.8). Life-threatening and rare fatal infections have been reported in association with sphingosine 1-phosphate (S1P) receptor modulators.</p><p>&nbsp;</p><p>Before initiating treatment with ponesimod, results from a recent complete blood count (CBC) with differential (including lymphocyte count) (i.e., within 6 months or after discontinuation of prior therapy) should be reviewed. Assessments of CBC are also recommended periodically during treatment. Absolute lymphocyte counts &lt;0.2 x 10<sup>9</sup>/L, if confirmed, should lead to interruption of ponesimod therapy until the level reaches &gt;0.8 x 10<sup>9</sup>/L when re-initiation of ponesimod can be considered.</p><p>&nbsp;</p><p>Initiation of treatment with ponesimod should be delayed in patients with severe active infection until resolution.</p><p>&nbsp;</p><p>Effective diagnostic and therapeutic strategies should be employed in patients with symptoms of infection while on therapy. Suspension of treatment with ponesimod should be considered if a patient develops a serious infection.</p><p>&nbsp;</p><p>In the development program, pharmacodynamic effects, such as lowering effects on peripheral lymphocyte count, were restored to normal within 1 week after discontinuation of ponesimod. In the OPTIMUM study, peripheral lymphocyte counts were restored to normal within 2 weeks after discontinuation of ponesimod, which was the first timepoint evaluated. Vigilance for signs and symptoms of infection should be continued for 1-2 weeks after ponesimod is discontinued (see below and section 4.8).</p><p>&nbsp;</p><p><em>Herpes viral infections</em></p><p>Cases of herpes viral infection have been reported in the development program of ponesimod (see section 4.8).</p><p>&nbsp;</p><p>Patients without a healthcare professional confirmed history of varicella (chickenpox) or without documentation of a full course of vaccination against varicella zoster virus (VZV) should be tested for antibodies to VZV before initiating treatment. A full course of vaccination for antibody-negative patients with varicella vaccine is recommended prior to commencing treatment with ponesimod. The treatment with ponesimod should be delayed for 4 weeks after vaccination to allow the full effect of vaccination to occur. See Vaccinations section below.</p><p>&nbsp;</p><p><em>Cryptococcal infections</em></p><p>Cases of fatal cryptococcal meningitis (CM) and disseminated cryptococcal infections have been reported with other S1P receptor modulators. No cases of CM have been reported in</p><p>ponesimod-treated patients in the development program. Physicians should be vigilant for clinical symptoms or signs of CM. Patients with symptoms or signs consistent with a cryptococcal infection should undergo prompt diagnostic evaluation and treatment. Ponesimod treatment should be suspended until a cryptococcal infection has been excluded. If CM is diagnosed, appropriate treatment should be initiated.</p><p>&nbsp;</p><p><em>Progressive multifocal leukoencephalopathy</em></p><p>Progressive multifocal leukoencephalopathy (PML) is an opportunistic viral infection of the brain caused by the JC virus (JCV) that typically only occurs in patients who are immunocompromised, and that usually leads to death or severe disability. Typical symptoms associated with PML are diverse, progress over days to weeks, and include progressive weakness on one side of the body or clumsiness of limbs, disturbance of vision, and changes in thinking, memory, and orientation leading to confusion and personality changes.</p><p>&nbsp;</p><p>No cases of PML have been reported in ponesimod-treated patients in the development program; however, PML has been reported in patients treated with a S1P receptor modulator and other multiple sclerosis (MS) therapies and has been associated with some risk factors (e.g., immunocompromised patients, polytherapy with immunosuppressants). Physicians should be vigilant for clinical symptoms or magnetic resonance imaging (MRI) findings that may be suggestive of PML. MRI findings may be apparent before clinical signs or symptoms. If PML is suspected, treatment with ponesimod should be suspended until PML has been excluded. If confirmed, treatment with ponesimod should be discontinued.</p><p>&nbsp;</p><p><em>Prior and concomitant treatment with anti-neoplastic, immune-modulating, or immunosuppressive therapies</em></p><p>In patients that are taking anti-neoplastic, immune-modulating, or immunosuppressive therapies (including corticosteroids), or if there is a history of prior use of these medicinal products, possible unintended additive immune system effects should be considered before initiating treatment with ponesimod (see section 4.5).</p><p>&nbsp;</p><p>When switching from medicinal products with prolonged immune effects, the half-life and mode of action of these medicinal products must be considered in order to avoid unintended additive effects on</p><p>&nbsp;</p><p>the immune system while at the same time minimising risk of disease reactivation, when initiating ponesimod.</p><p>&nbsp;</p><p>Pharmacokinetic/pharmacodynamic modeling indicates lymphocyte counts returned to the normal range in &gt;90% of healthy subjects within 1 week of stopping ponesimod therapy (see section 5.1). In the development program, pharmacodynamic effects, such as lowering of peripheral lymphocyte counts, were restored to normal within 1 week after the last dose.</p><p>&nbsp;</p><p>Use of immunosuppressants may lead to an additive effect on the immune system, and therefore caution should be applied up to 1 week after the last dose of ponesimod (see section 4.5).</p><p>&nbsp;</p><p><em>Vaccinations</em></p><p>No clinical data are available on the efficacy and safety of vaccinations in patients taking ponesimod. Vaccinations may be less effective if administered during ponesimod treatment.</p><p>&nbsp;</p><p>Avoid the use of live attenuated vaccines while patients are taking ponesimod. If the use of live attenuated vaccine immunisation is required, ponesimod treatment should be paused from 1 week prior to 4 weeks after a planned vaccination (see section 4.5).</p><p>&nbsp;</p><p><u>Macular oedema</u></p><p>&nbsp;</p><p>Ponesimod increases the risk of macular oedema (see section 4.8). An ophthalmic evaluation of the fundus, including the macula, is recommended in all patients before starting treatment and again at any time if a patient reports any change in vision while on ponesimod therapy.</p><p>&nbsp;</p><p>In the clinical trial experience in patients with all doses of ponesimod, the rate of macular oedema was 0.7%, the majority of patients had pre-existing risk factors or comorbid conditions. Most cases occurred within the first 6 months of therapy.</p><p>&nbsp;</p><p>Ponesimod therapy should not be initiated in patients with macular oedema until resolution.</p><p>&nbsp;</p><p>Continuation of ponesimod therapy in patients with macular oedema has not been evaluated. Patients who present with visual symptoms of macular oedema should be evaluated and, if confirmed, treatment with ponesimod should be discontinued. A decision on whether ponesimod should be</p><p>re-initiated after resolution needs to take into account the potential benefits and risks for the individual patient.</p><p>&nbsp;</p><p><em>Macular oedema in patients with a history of uveitis or diabetes mellitus</em></p><p>Patients with a history of uveitis and patients with diabetes mellitus are at increased risk of macular oedema during therapy with S1P receptor modulators. Therefore, these patients should have regular examinations of the fundus, including the macula, prior to treatment initiation with ponesimod and have follow-up evaluations while receiving therapy.</p><p>&nbsp;</p><p><u>Respiratory effects</u></p><p>&nbsp;</p><p>Dose-dependent reductions in forced expiratory volume over 1 second (FEV1) and reductions in diffusion lung capacity for carbon monoxide (DLCO) were observed in ponesimod-treated patients mostly occurring in the first month after treatment initiation (see section 4.8). Respiratory symptoms associated with ponesimod treatment can be reversed with administration of a short-acting beta2 agonist.</p><p>&nbsp;</p><p>Ponesimod should be used with caution in patients with severe respiratory disease, pulmonary fibrosis and chronic obstructive pulmonary disease. Spirometry evaluation of respiratory function should be performed during therapy with ponesimod if clinically indicated.</p><p>&nbsp;</p><p><u>Liver injury</u></p><p>&nbsp;</p><p>Elevations of transaminases may occur in ponesimod-treated patients (see section 4.8). Recent (i.e., within last 6 months) transaminase and bilirubin levels should be reviewed before initiation of ponesimod therapy.</p><p>&nbsp;</p><p>Patients who develop symptoms suggestive of hepatic dysfunction, such as unexplained nausea, vomiting, abdominal pain, fatigue, anorexia, rash with eosinophilia, or jaundice and/or dark urine during treatment, should be monitored for hepatotoxicity. Ponesimod should be discontinued if significant liver injury is confirmed (for example, ALT exceeds 3 -fold ULN and total bilirubin exceeds 2 -fold ULN).</p><p>&nbsp;</p><p>Although there are no data to establish that patients with pre-existing liver disease are at increased risk to develop elevated liver function test values when taking ponesimod, caution should be exercised when using ponesimod in patients with a history of significant liver disease (see section 4.2).</p><p>&nbsp;</p><p><u>Increased blood pressure</u></p><p>&nbsp;</p><p>A mild reversible increase in blood pressure (mean change less than 3 mmHg) was observed in patients treated with ponesimod (see section 4.8). Blood pressure should be regularly monitored during treatment with ponesimod and managed appropriately.</p><p>&nbsp;</p><p><u>Cutaneous neoplasm</u></p><p>&nbsp;</p><p>As there is a potential risk of skin malignancies (see section 4.8), patients treated with ponesimod should be cautioned against exposure to sunlight without protection. These patients should not receive concomitant phototherapy with UV-B-radiation or PUVA-photochemotherapy.</p><p>&nbsp;</p><p><u>Women of childbearing potential</u></p><p>&nbsp;</p><p>Based on animal studies, ponesimod may cause fetal harm. Due to the risk to the foetus, ponesimod is contraindicated during pregnancy and in women of childbearing potential not using effective contraception (see sections 4.3 and 4.6). Before initiation of treatment in women of childbearing potential, a negative pregnancy test result must be available (see section 4.6). Because it takes approximately 1 week to eliminate ponesimod from the body, women of childbearing potential should use effective contraception to avoid pregnancy during and for 1 week after stopping ponesimod treatment.</p><p>&nbsp;</p><p><u>Posterior reversible encephalopathy syndrome</u></p><p>&nbsp;</p><p>Rare cases of posterior reversible encephalopathy syndrome (PRES) have been reported in patients receiving a S1P receptor modulator. Such events have not been reported for ponesimod-treated patients in the development program. However, should a ponesimod-treated patient develop any unexpected neurological or psychiatric symptoms/signs (e.g., cognitive deficits, behavioral changes, cortical visual disturbances, or any other neurological cortical symptoms/signs), any symptom/sign suggestive of an increase of intracranial pressure, or accelerated neurological deterioration, the physician should promptly schedule a complete physical and neurological examination and should consider a MRI. Symptoms of PRES are usually reversible but may evolve into ischaemic stroke or cerebral haemorrhage. Delay in diagnosis and treatment may lead to permanent neurological sequelae. If PRES is suspected, ponesimod should be discontinued.</p><p>&nbsp;</p><p><u>Return of disease activity after ponesimod discontinuation</u></p><p>&nbsp;</p><p>Severe exacerbation of disease, including disease rebound, has been rarely reported after discontinuation of a S1P receptor modulator. The possibility of severe exacerbation of disease should be considered after stopping ponesimod treatment. Patients should be observed for a severe</p><p>&nbsp;</p><p>exacerbation or return of high disease activity upon ponesimod discontinuation and appropriate treatment should be instituted, as required (see above).</p><p>&nbsp;</p><p><u>Excipients</u></p><p>&nbsp;</p><p><em>Lactose</em></p><p>Ponvory contains lactose (see section 2). Patients with rare hereditary problems of galactose intolerance, total lactase deficiency or glucose-galactose malabsorption should not take this medicinal product.</p><p>&nbsp;</p><p><em>Sodium</em></p><p>This medicinal product contains less than 1 mmol sodium (23 mg) per tablet, that is to say essentially &lsquo;sodium-free&rsquo;.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Anti-neoplastic, immune-modulating, or immunosuppressive therapies</u></p><p>&nbsp;</p><p>Ponesimod has not been studied in combination with anti-neoplastic, immune-modulating, or immunosuppressive therapies. Caution should be used during concomitant administration because of the risk of additive immune effects during such therapy and in the weeks following administration (see section 4.4).</p><p>&nbsp;</p><p><u>Anti-arrhythmic medicinal products, QT prolonging medicinal products, medicinal products that may</u> <u>decrease heart rate</u></p><p>&nbsp;</p><p>Ponesimod has not been studied in patients taking QT prolonging medicinal products (see section 4.4). <u>Beta-blockers</u></p><p>The negative chronotropic effect of co-administration of ponesimod and propranolol was evaluated in a dedicated pharmacodynamics safety study. The addition of ponesimod to propranolol at steady state has an additive effect on HR effect.</p><p>&nbsp;</p><p>In a drug-drug interaction study, the up-titration regimen of ponesimod (see section 4.2) was administered to subjects receiving propranolol (80 mg) once daily at steady-state. Compared to ponesimod alone, the combination with propranolol after the first dose of ponesimod (2 mg) had a</p><p>12.4 bpm (90% CI: -15.6 to -9.1) decrease in mean hourly heart rate and at the first dose of ponesimod (20 mg) after up-titration a 7.4 bpm (90% CI: -10.9 to -3.9) decrease in mean hourly heart rate. No significant changes in pharmacokinetics of ponesimod or propranolol were observed.</p><p>&nbsp;</p><p><u>Vaccines</u></p><p>&nbsp;</p><p>Vaccinations may be less effective if administered while being treated with ponesimod and up to 1 week after its discontinuation (see section 4.4).</p><p>&nbsp;</p><p>The use of live attenuated vaccines may carry the risk of infection and should therefore be avoided during ponesimod treatment and up to 1 week after its discontinuation of treatment with ponesimod (see section 4.4).</p><p>&nbsp;</p><p><u>Effect of other medicinal products on ponesimod</u></p><p>&nbsp;</p><p>Medicinal products that are inhibitors of major CYP or UGT enzymes are unlikely to impact the pharmacokinetics of ponesimod (see section 5.2).</p><p>&nbsp;</p><p>Co-administration of ponesimod with strong inducers of multiple metabolic pathways of ponesimod (see section 5.2) may decrease the systemic exposure of ponesimod. It is unclear whether this decrease is clinically relevant.</p><p>&nbsp;</p><p>Ponesimod is not a substrate of P-gp, BCRP, OATP1B1 or OATP1B3 transporters. Medicinal products that are inhibitors of these transporters are unlikely to impact the pharmacokinetics of ponesimod.</p><p>&nbsp;</p><p><u>Effect of ponesimod on other medicinal products</u></p><p>&nbsp;</p><p>Ponesimod and its metabolites are unlikely to show any clinically relevant drug-drug interaction potential for CYP or UGT enzymes, or transporters (see section 5.2).</p><p>&nbsp;</p><p><u>Oral contraceptives</u></p><p>&nbsp;</p><p>Co-administration of ponesimod, with an oral hormonal contraceptive (containing 1 mg norethisterone/norethindrone and 35 mcg ethinyl estradiol) showed no clinically relevant pharmacokinetic interaction with ponesimod. Therefore, concomitant use of ponesimod is not expected to decrease the efficacy of hormonal contraceptives. No interaction studies have been performed with oral contraceptives containing other progestogens; however, an effect of ponesimod on their exposure is not expected.</p><p>&nbsp;</p><p><u>Paediatric population</u></p><p>&nbsp;</p><p>Interaction studies have only been performed in adults.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Women of childbearing potential/Contraception in females</u></p><p>&nbsp;</p><p>Ponvory is contraindicated in women of childbearing potential not using effective contraception (see section 4.3). Before initiation of Ponvory treatment in women of childbearing potential a negative pregnancy test result must be available, and women should be counselled on the potential for a serious risk to the foetus and the need for effective contraception during treatment with ponesimod. Since it takes approximately 1 week to eliminate ponesimod from the body after stopping treatment, the potential risk to the foetus may persist and women must use effective contraception during this period (see section 4.4).</p><p>&nbsp;</p><p>Specific measures are also included in the Healthcare Professional checklist. These measures must be implemented before ponesimod is prescribed to female patients and during treatment.</p><p>&nbsp;</p><p>When stopping ponesimod therapy for planning a pregnancy the possible return of disease activity should be considered (see section 4.4).</p><p>&nbsp;</p><p><u>Pregnancy</u></p><p>&nbsp;</p><p>Ponvory is contraindicated during pregnancy (see section 4.3). Although there are no data from the use of ponesimod in pregnant women, studies in animals have shown reproductive toxicity (see</p><p>section 5.3). If a woman becomes pregnant during treatment, ponesimod must be immediately discontinued. Medical advice should be given regarding the risk of harmful effects to the foetus associated with treatment (see section 5.3) and follow-up examinations should be performed.</p><p>&nbsp;</p><p>Based on clinical experience in patients receiving another S1P receptor modulator, the use is associated with an increased risk of major congenital malformations.</p><p>&nbsp;</p><p><u>Breast-feeding</u></p><p>&nbsp;</p><p>It is unknown whether ponesimod or its metabolites are excreted in human milk. A study in lactating rats has indicated excretion of ponesimod in milk (see section 5.3). A risk to newborns/infants cannot be excluded. Ponvory should not be used during breast-feeding.</p><p>&nbsp;</p><p><u>Fertility</u></p><p>&nbsp;</p><p>The effect of ponesimod on human fertility has not been evaluated. Data from preclinical studies do not suggest that ponesimod would be associated with an increased risk of reduced fertility (see section 5.3).</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Ponvory has no or negligible influence on the ability to drive and use machines.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Summary of the safety profile</u></p><p>&nbsp;</p><p>The most commonly reported adverse drug reactions are nasopharyngitis (19.7%), alanine aminotransferase increased (17.9%) and upper respiratory tract infection (11%).</p><p>&nbsp;</p><p><u>Tabulated list of adverse reactions</u></p><p>&nbsp;</p><p>Adverse reactions reported with ponesimod in controlled clinical trials and uncontrolled extension trials are ranked by frequency, with the most frequent reactions first. Frequencies were defined using the following convention: very common (&ge;1/10); common (&ge;1/100 to &lt;1/10); uncommon (&ge;1/1,000 to</p><p>&lt;1/100); rare (&ge;1/10,000 to &lt;1/1,000); very rare (&lt;1/10,000); not known (cannot be estimated from the available data).</p><p>&nbsp;</p><p>Table 2:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Tabulated list of adverse reactions</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>System Organ Class (SOC)</strong></p></td><td style="vertical-align:top"><p><strong>Very common</strong></p></td><td style="vertical-align:top"><p><strong>Common</strong></p></td><td style="vertical-align:top"><p><strong>Uncommon</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>Infections and infestations</strong></p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p>nasopharyngitis, upper respiratory tract infection</p></td><td style="vertical-align:top"><p>urinary tract infection, bronchitis, influenza, rhinitis, respiratory tract infection, respiratory tract infection viral, pharyngitis, sinusitis, viral infection, herpes zoster,</p><p>laryngitis, pneumonia</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Blood and</strong></p><p><strong>lymphatic system disorders</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>lymphopenia, lymphocyte count decreased</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Psychiatric disorders</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>depression, insomnia, anxiety</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Nervous system disorders</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>dizziness, hypoaesthesia, somnolence, migraine,</p><p>seizure</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Eye disorders</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>macular oedema</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Ear and labyrinth disorders</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>vertigo</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Cardiac disorders</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>bradycardia</p></td></tr><tr><td style="vertical-align:top"><p><strong>Vascular disorders</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>hypertension</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Respiratory, thoracic and mediastinal</strong></p><p><strong>disorders</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p><p>dyspnoea, cough</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Gastrointestinal disorders</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>dyspepsia</p></td><td style="vertical-align:top"><p>dry mouth</p></td></tr><tr><td style="vertical-align:top"><p><strong>Musculoskeletal and connective</strong></p><p><strong>tissue disorders</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>back pain, arthralgia, pain in extremity, ligament</p><p>sprain</p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p><p>joint swelling</p></td></tr><tr><td style="vertical-align:top"><p><strong>General disorders and</strong></p><p><strong>administration site conditions</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>fatigue, pyrexia, oedema peripheral, chest discomfort</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>Investigations</strong></p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p>alanine aminotransferase increased</p></td><td style="vertical-align:top"><p>aspartate aminotransferase increased, hypercholesterolaemia, hepatic enzyme increased, C-reactive protein increased, transaminases increased, blood</p><p>cholesterol increased</p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p>hyperkalaemia</p></td></tr></tbody></table><p><strong>&nbsp;</strong></p><p><u>Description of selected adverse reactions</u></p><p>&nbsp;</p><p><em>Bradyarrhythmia</em></p><p>In the Phase 3 OPTIMUM study (see section 5.1), bradycardia at treatment initiation (sinus bradycardia/HR less than 50 bpm on ECG on day 1) occurred in 5.8% of ponesimod-treated patients compared to 1.6% of patients receiving teriflunomide 14 mg. Patients who experienced bradycardia were generally asymptomatic. Bradycardia resolved in all patients without intervention and did not require discontinuation of ponesimod treatment. On day 1, 3 patients treated with ponesimod had asymptomatic post-dose HR below or equal to 40 bpm; all 3 patients had baseline HRs below 55 bpm.</p><p>&nbsp;</p><p>Initiation of ponesimod treatment has been associated with transient AV conduction delays that follow a similar temporal pattern as the observed decrease in HR during dose titration. The AV conduction delays manifested as first-degree AV block (prolonged PR interval on ECG), which occurred in 3.4% of ponesimod -treated patients and in 1.2% of patients receiving teriflunomide 14 mg in the OPTIMUM study. No second-degree AV blocks, Mobitz type I (Wenckebach), were observed in OPTIMUM. The conduction abnormalities typically were transient, asymptomatic, resolved within</p><p>24 hours, resolved without intervention, and did not require discontinuation of ponesimod treatment.</p><p>&nbsp;</p><p><em>Infections</em></p><p>In the Phase 3 OPTIMUM study (see section 5.1), the overall rate of infections was comparable between the ponesimod-treated patients and those receiving teriflunomide 14 mg (54.2% vs 52.1% respectively). Nasopharyngitis and viral infections were more common in ponesimod-treated patients. Serious or severe infections occurred at a rate of 1.6% in ponesimod-treated patients compared to 0.9% of patients receiving teriflunomide 14 mg.</p><p>&nbsp;</p><p>In OPTIMUM, the rate of herpetic infections was not different between the ponesimod-treated patients and those receiving teriflunomide 14 mg (4.8%).</p><p>&nbsp;</p><p><em>Blood lymphocyte count reduction</em></p><p>In OPTIMUM, 3.2% of ponesimod-treated patients compared to none of the patients receiving teriflunomide 14 mg, experienced lymphocyte counts less than 0.2 x 10<sup>9</sup>/L with values generally resolving to greater than 0.2 x 10<sup>9</sup>/L while remaining on treatment with ponesimod.</p><p>&nbsp;</p><p><em>Macular oedema</em></p><p>In OPTIMUM, macular oedema was reported in 1.1% of ponesimod-treated patients compared to none of the patients receiving teriflunomide 14 mg.</p><p>&nbsp;</p><p><em>Liver enzymes elevation</em></p><p>In the OPTIMUM study, ALT increased to three and five times the upper limit of normal (ULN) in 17.3% and 4.6% of ponesimod-treated patients, respectively, compared to 8.3% and 2.5% of patients receiving, teriflunomide 14 mg, respectively. ALT increased eight times ULN in 0.7%</p><p>ponesimod-treated patients compared to 2.1% in patients receiving teriflunomide 14 mg. The majority of elevations occurred within 6 or 12 months of starting treatment. ALT levels returned to normal after discontinuation of ponesimod. Most cases of ALT increases &ge;3&times;ULN resolved on continued ponesimod treatment, and the remaining cases resolved upon treatment discontinuation. In clinical trials, ponesimod was discontinued if the elevation exceeded a 3 -fold increase and the patient showed symptoms related to hepatic dysfunction.</p><p>&nbsp;</p><p><em>Respiratory effects</em></p><p>Dose-dependent reductions in forced expiratory volume over 1 second (FEV1) were observed in patients treated with ponesimod (see section 4.4). In OPTIMUM, a higher proportion of ponesimod- treated patients (19.4%) had a reduction of more than 20% from baseline in percent predicted FEV1 compared to 10.6% of patients receiving teriflunomide 14 mg. The reduction from baseline in percent predicted FEV1 at 2 years was 8.3% in ponesimod-treated patients compared to 4.4% in patients receiving teriflunomide 14 mg. The changes in FEV1 and DLCO appear to be partially reversible after treatment discontinuation. In the OPTIMUM study, 7 patients discontinued ponesimod because of pulmonary adverse events (dyspnoea). Ponesimod has been tested in MS patients with mild to moderate asthma or chronic obstructive pulmonary disease. The changes in FEV1 were similar in this subgroup compared with the subgroup of patients without baseline lung disorders.</p><p>&nbsp;</p><p><em>Increased blood pressure</em></p><p>In OPTIMUM, ponesimod-treated patients had an average increase of 2.9 mmHg in systolic blood pressure and 2.8 mmHg in diastolic blood pressure compared to 2.8 mmHg and 3.1 mmHg in patients receiving teriflunomide 14 mg, respectively. An increase in blood pressure with ponesimod was first detected after approximately 1 month of treatment initiation and persisted with continued treatment. The blood pressure values after ponesimod treatment discontinuation indicate reversibility.</p><p>&nbsp;</p><p>Hypertension was reported as an adverse reaction in 10.1% of ponesimod-treated patients and in 9.0% of patients receiving teriflunomide 14 mg.</p><p>&nbsp;</p><p><em>Cutaneous neoplasm</em></p><p>In OPTIMUM, a case of malignant melanoma and two cases of basal cell carcinoma (0.4%) were reported in ponesimod-treated patients compared to one case of basal cell carcinoma (0.2%) in patients receiving teriflunomide 14 mg. An increased risk of cutaneous malignancies has been reported in association with another S1P receptor modulator.</p><p>&nbsp;</p><p><u>Reporting of suspected adverse reactions</u></p><p>Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product.</p><p>&nbsp;</p><p>To report any Side Effect(s):</p><p><strong>&nbsp;</strong></p><p>&bull;&nbsp;&nbsp; <strong>Saudi Arabia</strong></p><p>&nbsp;</p><p>The National Pharmacovigilance Centre (NPC):</p><p>SFDA Call Center: 19999</p><p>E-mail: npc.drug@sfda.gov.sa</p><p>Website: https://ade.sfda.gov.sa/</p><p>&nbsp;</p><p><strong>Other GCC States:</strong></p><p>Please contact the relevant competent authority</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Symptoms and signs</u></p><p>&nbsp;</p><p>In patients with overdose of ponesimod, especially upon initiation/re-initiation of treatment, it is important to observe for signs and symptoms of bradycardia as well as AV conduction blocks, which may include overnight monitoring. Regular measurements of pulse rate and blood pressure are required, and ECGs should be performed (see sections 4.4, 4.8 and 5.1).</p><p>&nbsp;</p><p><u>Treatment</u></p><p>&nbsp;</p><p>There is no specific antidote to ponesimod. Neither dialysis nor plasma exchange would result in meaningful removal of ponesimod from the body. The decrease in heart rate induced by ponesimod can be reversed by atropine.</p><p>&nbsp;</p><p>In the event of overdose, ponesimod should be discontinued, and general supportive treatment given until clinical toxicity has been diminished or resolved. It is advisable to contact a poison control centre to obtain the latest recommendations for the management of an overdose.</p><p>&nbsp;</p><p>&nbsp;</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: Immunosuppressants, selective immunosuppressants, ATC code: L04AA50</p><p>&nbsp;</p><p><u>Mechanism of action</u></p><p>&nbsp;</p><p>Ponesimod is a sphingosine 1-phosphate (S1P) receptor 1 modulator. Ponesimod binds with high affinity to S1P receptor 1 located on lymphocytes.</p><p>&nbsp;</p><p>Ponesimod blocks the capacity of lymphocytes to egress from lymph nodes reducing the number of lymphocytes in peripheral blood. The mechanism by which ponesimod exerts therapeutic effects in multiple sclerosis may involve reduction of lymphocyte migration into the central nervous system.</p><p>&nbsp;</p><p><u>Pharmacodynamic effects</u></p><p>&nbsp;</p><p><em>Immune system</em></p><p>In healthy volunteers, ponesimod induces a dose-dependent reduction of the peripheral blood lymphocyte count from a single dose of 5 mg onwards, with the greatest reduction observed 6 hours post-dose, caused by reversible sequestration of lymphocytes in lymphoid tissues. After 7 daily doses of 20 mg, the greatest decrease in absolute mean lymphocyte count was to 26% of baseline</p><p>(650 cells/&micro;L), observed 6 hours after administration. Peripheral blood B cells [CD19+] and T cells [CD3+], T-helper [CD3+CD4+], and T-cytotoxic [CD3+CD8+] cell subsets are all affected, while NK cells are not. T-helper cells were more sensitive to the effects of ponesimod than T-cytotoxic cells.</p><p>&nbsp;</p><p>Pharmacokinetic/Pharmacodynamic modelling indicates lymphocyte counts returned to the normal range in &gt;90% of healthy subjects within 1 week of stopping therapy. In the development program, peripheral lymphocyte counts returned to the normal range within 1 week after discontinuation of ponesimod.</p><p>&nbsp;</p><p>In the OPTIMUM study, lymphocyte counts returned to the normal range in 94% of patients and to above 0.8 x 10<sup>9</sup> cells/L in 99% of patients at the first scheduled follow-up visit (day 15) upon discontinuation of ponesimod treatment.</p><p>&nbsp;</p><p><em>Heart rate and rhythm</em></p><p>Ponesimod causes a transient dose dependent reduction in HR and AV conduction delays upon treatment initiation (see section 4.4). The HR decreases plateaued at doses greater than or equal to</p><p>40 mg, and bradyarrhythmic events (AV blocks) were detected at a higher incidence under ponesimod treatment, compared to placebo. This effect starts within the first hour of dosing and is maximal at</p><p>2-4 hours post-dose and HR generally returns to pre-dose values by 4-5 hours post-dose on day 1 and the effect diminishes with repeated administration, indicating tolerance.</p><p>&nbsp;</p><p>With the gradual up-titration of ponesimod, the HR reduction is less pronounced and no second-degree AV blocks of Mobitz type II or higher degree were observed.</p><p>&nbsp;</p><p>The decrease in HR induced by ponesimod can be reversed by atropine.</p><p>&nbsp;</p><p><em>Effect on QT/QTc interval and cardiac electrophysiology</em></p><p>In a thorough QT study of supra-therapeutic doses of 40 mg and 100 mg (2 - and 5 -fold respectively, the recommended maintenance dose) ponesimod at steady-state, ponesimod treatment resulted in mild prolongation of individually corrected QT (QTcI) interval, with the upper bound of 90% two-sided confidence interval (CI) at 11.3 ms (40 mg) and 14.0 ms (100 mg). There was no consistent signal of increased incidence of QTcI outliers associated with ponesimod treatment, either as absolute values or change from baseline. Based on the concentration-effect relationship, no clinically relevant effect on QTc interval is expected for the therapeutic dose of 20 mg (see section 4.4).</p><p>&nbsp;</p><p><em>Pulmonary function</em></p><p>Dose-dependent reductions in absolute forced expiratory volume over 1 second were observed in ponesimod-treated subjects and were greater than in subjects taking placebo (see section 4.8).</p><p>&nbsp;</p><p><u>Clinical efficacy and safety</u></p><p>&nbsp;</p><p>The efficacy of ponesimod was evaluated in the phase 3 study, OPTIMUM, a multicentre, randomised, double blind, parallel group active-controlled superiority study in patients with relapsing MS (RMS) treated for 108 weeks. The study included patients with relapsing course of MS from onset (RRMS or SPMS with superimposed relapses) and an Expanded Disability Status Scale (EDSS) score of 0 to 5.5, having experienced at least one relapse within the prior year, or two relapses within the prior two years, or having at least one gadolinium-enhancing (Gd+) lesion on a brain MRI within the prior</p><p>6 months or at baseline.</p><p>&nbsp;</p><p>Patients were randomised to receive either once daily ponesimod or teriflunomide 14 mg, beginning with a 14-day dose titration (see section 4.2). Neurological evaluations were performed every</p><p>12 weeks as well as at the time of a suspected relapse. Brain MRIs were performed at baseline and at Weeks 60 and 108.</p><p>&nbsp;</p><p>The primary endpoint of the study was the annualised relapse rate (ARR) from baseline up to end of study (EOS). The prespecified hierarchical fallback testing sequence included the primary endpoint and the secondary endpoints: cumulative number of combined unique active lesions (CUAL, defined as new Gd+ T1 lesions plus new or enlarging T2 lesions [without double-counting of lesions]) from baseline to Week 108; time to 12-week confirmed disability accumulation (CDA) from baseline to EOS; and time to 24-week CDA from baseline to EOS. A 12-week CDA was defined as an increase of at least 1.5 in EDSS for subjects with a baseline EDSS score of 0 or an increase of at least 1.0 in EDSS for subjects with a baseline EDSS score of 1.0 to 5.0, or an increase of at least 0.5 in EDSS for subjects with a baseline EDSS score &ge;5.5 which was confirmed after 12 weeks.</p><p>&nbsp;</p><p>In OPTIMUM, 1133 patients were randomised to either ponesimod (N=567) or teriflunomide 14 mg (N=566); 86.4% of ponesimod-treated patients and 87.5% of teriflunomide 14 mg-treated patients completed the study as per protocol. The baseline demographic and disease characteristics were balanced between the treatment groups. At baseline, the mean age of patients was 37 years (standard deviation 8.74), 97% were white and 65% were female. The mean disease duration was 7.6 years, the mean number of relapses in the previous year was 1.3, and the mean EDSS score was 2.6; 57% of patients had not received any prior disease-modifying treatments (DMT) for MS. At baseline, 40% of ponesimod-treated patients had one or more Gd+ T1 lesions on brain MRI (mean 1.9).</p><p>&nbsp;</p><p>Results are presented in Table 3. Analysis of patient populations with differing baseline levels of disease activity, including active and highly active disease, showed that the efficacy of ponesimod on the primary and secondary endpoints was consistent with the overall population.</p><p>&nbsp;</p><p>Table 3:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; OPTIMUM study efficacy results</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><strong>Ponesimod 20 mg</strong></p></td><td style="vertical-align:top"><p><strong>Teriflunomide 14 mg</strong></p></td></tr><tr><td style="vertical-align:top"><p>Clinical endpoint</p></td><td style="vertical-align:top"><p>N=567</p></td><td style="vertical-align:top"><p>N=566</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p>Primary endpoint</p></td></tr><tr><td style="vertical-align:top"><p>Mean Annualised Relapse Rate<sup>a</sup></p></td><td style="vertical-align:top"><p>0.202</p></td><td style="vertical-align:top"><p>0.290</p></td></tr><tr><td style="vertical-align:top"><p>Relative rate reduction</p></td><td colspan="2" style="vertical-align:top"><p>30.5% (p=0.0003)<sup>*</sup></p><p>(95% CLs: 15.2%, 43.0%)</p></td></tr><tr><td style="vertical-align:top"><p>Patients with at least one confirmed relapse</p></td><td style="vertical-align:top"><p>29.3%</p></td><td style="vertical-align:top"><p>39.4%</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p>Secondary endpoints</p></td></tr><tr><td style="vertical-align:top"><p>Confirmed Disability Accumulation (CDA) <sup>b</sup></p></td><td style="vertical-align:top"><p>N=567</p></td><td style="vertical-align:top"><p>N=566</p></td></tr><tr><td style="vertical-align:top"><p>Patients<sup>b</sup> with 12-week CDA</p></td><td style="vertical-align:top"><p>10.8%</p></td><td style="vertical-align:top"><p>13.2%</p></td></tr><tr><td style="vertical-align:top"><p>Relative risk reduction<sup>c</sup></p></td><td colspan="2" style="vertical-align:top"><p>17% (p=0.2939)</p><p>(95% CLs: -18%, 42%)</p></td></tr><tr><td style="vertical-align:top"><p>Patients<sup>b</sup> with 24-week CDA</p></td><td style="vertical-align:top"><p>8.7%</p></td><td style="vertical-align:top"><p>10.5%</p></td></tr><tr><td style="vertical-align:top"><p>Relative risk reduction<sup>c</sup></p></td><td colspan="2" style="vertical-align:top"><p>16% (p=0.3720)</p><p>(95% CLs: -24%, 43%)</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>MRI Endpoints</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Cumulative number of Combined Unique Active Lesions (CUALs)</p></td><td style="vertical-align:top"><p>N=539</p></td><td style="vertical-align:top"><p>N=536</p></td></tr><tr><td style="vertical-align:top"><p>Mean number of CUALs per year<sup>d</sup></p></td><td style="vertical-align:top"><p>1.41</p></td><td style="vertical-align:top"><p>3.16</p></td></tr><tr><td style="vertical-align:top"><p>Relative reduction</p></td><td colspan="2" style="vertical-align:top"><p>56% (p&lt;0.0001)<sup>*</sup></p><p>(95% CLs: 45.8%, 63.6%)</p></td></tr></tbody></table><p>All analyses are based on the full analysis set (FAS), which includes all randomised patients.&ldquo;N&rdquo; refers to the number of patients included in each of the endpoint analysis, per treatment group.</p><p>a&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Defined as confirmed relapses per year up to end of study (negative binomial regression model with stratification variables (EDSS &le; 3.5 versus EDSS &gt; 3.5; DMT within last 2 years prior to randomisation [Yes/No]) and the number of relapses in the year prior to study entry(&lt;=1, &gt;=2) as covariates)</p><p>b&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Based on time to first 12-Week/24-Week CDA event up to end of study (Kaplan-Meier estimates at Week 108)</p><p>c&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Defined as time to 12-Week/24-Week CDA from baseline to end of study (Stratified Cox proportional hazard model, p value based on the stratified log rank test). Two pre-planned indirect comparison methods both showed a consistent clinically meaningful effect of ponesimod compared to placebo on time to first 12-week CDA, the Matching-Adjusted Indirect Comparison (MAIC) approach showed that ponesimod reduced 12-week CDA by 40% compared to placebo (hazard ratio: 0.60 [95% CI: 0.34, 1.05]) and the Model-Based Meta-Analysis (MBMA) showed that ponesimod reduced the risk of 12-week CDA by 39% compared to placebo (hazard ratio: 0.61 [95% CLs: 0.47, 0.80]).</p><p>d&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Defined as new Gd+ T1 lesions plus new or enlarging T2 lesions [without double-counting of lesions] per year from baseline to Week 108 (Negative binomial regression model with stratification factors and Gd+ T1 lesions (present/absent) at baseline as covariates)</p><p>* statistically significant according to the predefined multiplicity testing strategy, CLs: Confidence Limits</p><p>&nbsp;</p><p><u>Paediatric population</u></p><p>&nbsp;</p><p>The European Medicines Agency has deferred the obligation to submit the results of studies with Ponvory in one or more subsets of the paediatric population in the treatment of multiple sclerosis (see 4.2 for information on paediatric use).</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>&nbsp;</strong></p><p>The pharmacokinetics of ponesimod is similar in healthy subjects and subjects with multiple sclerosis. The pharmacokinetic profile of ponesimod showed &ldquo;low to moderate&rdquo; inter-subject variability, approximately 6% &ndash; 33%, and &ldquo;low&rdquo; intra-subject variability, approximately 12% - 20%.</p><p>&nbsp;</p><p><u>Absorption</u></p><p>&nbsp;</p><p>The time to reach maximum plasma concentration of ponesimod is 2-4 hours post-dose. The absolute oral bioavailability of a 10 mg dose is 83.8%.</p><p>&nbsp;</p><p><em>Food effect</em></p><p>Food does not have a clinically relevant effect on ponesimod pharmacokinetics, therefore ponesimod may be taken with or without food.</p><p>&nbsp;</p><p><u>Distribution</u></p><p>&nbsp;</p><p>Following intravenous administration in healthy subjects, the steady-state volume of distribution of ponesimod is 160 L.</p><p>&nbsp;</p><p>Ponesimod is highly bound to plasma proteins, (&gt; 99%) and is mainly (78.5%) distributed in the plasma fraction of whole blood. Animal studies show that ponesimod readily crosses the</p><p>blood-brain-barrier. <u>Biotransformation</u></p><p>Ponesimod is extensively metabolised prior to excretion in humans, though unchanged ponesimod was the main circulating component in plasma. Two inactive circulating metabolites, M12 and M13, have also been identified in human plasma. M13 is approximately 20% and M12 is 6% of total drug-related exposure. Both metabolites are inactive at S1P receptors at concentrations achieved with therapeutic doses of ponesimod.</p><p>&nbsp;</p><p><em>In vitro </em>studies with human liver preparations indicate that metabolism of ponesimod occurs through multiple, distinct enzyme systems, including multiple CYP450 (CYP2J2, CYP3A4, CYP3A5, CYP4F3A, and CYP4F12), UGT (mainly UGT1A1 and UGT2B7) and non CYP450 oxidative enzymes, without major contribution by any single enzyme.</p><p>&nbsp;</p><p><em>In vitro </em>investigations indicate that at the therapeutic dose of 20 mg once-daily, ponesimod and its metabolite M13 do not show any clinically relevant drug-drug interaction potential for CYP or UGT enzymes, or transporters.</p><p>&nbsp;</p><p><u>Elimination</u></p><p>&nbsp;</p><p>After a single intravenous administration, the total clearance of ponesimod is 3.8 L/hour. The elimination half-life after oral administration is approximately 33 hours.</p><p>&nbsp;</p><p>Following a single oral administration of <sup>14</sup>C-ponesimod, 57% to 80% of the dose was recovered in faeces (16% as unchanged ponesimod), and 10% to18% in urine (no unchanged ponesimod).</p><p>&nbsp;</p><p><u>Linearity</u></p><p>&nbsp;</p><p>Following ponesimod oral dosing, Cmax and AUC increased approximately dose proportionally in the dose range studied (1-75 mg). Steady-state levels are approximately 2.0 to 2.6 -fold greater than with a single dose and are achieved following 4 days of administration of the maintenance dose of ponesimod.</p><p>&nbsp;</p><p><u>Specific populations</u></p><p>&nbsp;</p><p><em>Renal impairment</em></p><p>No dose adjustment is necessary in patients with renal impairment. In adult subjects with moderate or severe renal impairment (estimated creatinine clearance (CrCl) as determined by the Cockroft-Gault between 30-59 mL/min for moderate and &lt;30 mL/min for severe), there were no significant changes in ponesimod Cmax and AUC compared to subjects with normal renal function (CrCl&gt;90 mL/min). The effect of dialysis on the pharmacokinetics of ponesimod has not been studied. Due to the high plasma protein binding (greater than 99%) of ponesimod, dialysis is not expected to alter the total and unbound ponesimod concentration and no dose adjustments are anticipated based on these considerations.</p><p>&nbsp;</p><p><em>Hepatic impairment</em></p><p>In adult subjects without MS with mild, moderate or severe hepatic impairment (Child-Pugh class A, B and C, respectively, N=8 for each category), ponesimod AUC0-&infin; was increased by 1.3-, 2.0- and</p><p>3.1 -fold respectively compared to healthy subjects. Based on the population pharmacokinetic assessment in a larger group of subjects (N=1245), including 55 subjects with MS with mild hepatic impairment (classified based on the National Cancer Institute - Organ Dysfunction Working Group criteria), a 1.1-fold increase of ponesimod AUC0-&infin; was estimated, compared to subjects with normal&nbsp;hepatic function.</p><p>&nbsp;</p><p>Ponesimod is contraindicated in patients with moderate and severe hepatic impairment, as the risk of adverse reactions may be greater.</p><p>&nbsp;</p><p>No dose adjustment is needed in patients with mild hepatic impairment (Child-Pugh class A).</p><p>&nbsp;</p><p><em>Age</em></p><p>The results from a population pharmacokinetics analysis indicated that age (range: 17 to 65 years) does not significantly influence the pharmacokinetics of ponesimod. Ponesimod has not been investigated in the elderly population (&gt;65 years).</p><p>&nbsp;</p><p><em>Gender</em></p><p>Gender has no clinically significant influence on ponesimod pharmacokinetics.</p><p>&nbsp;</p><p><em>Race</em></p><p>No clinically relevant pharmacokinetic differences were observed between Japanese and Caucasian or Black and White subjects.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>In the lung, transient adaptive pulmonary histiocytosis and lung weight increase were observed in mice, rats, and dogs after 4 weeks of administration of ponesimod but were no longer present or were less pronounced after 13 to 52 weeks of administration. The no-observed-adverse-effect levels (NOAELs) for lung findings were identified in rat and dog 4-week toxicity studies and were associated with Cmax and AUC0-24 values similar or inferior to human systemic exposures following recommended human dose (RHD) of 20 mg/day.</p><p>&nbsp;</p><p>In the dog, arterial lesions observed in the heart were secondary to haemodynamic changes. The dog is known to be particularly sensitive to hemodynamic changes in the heart and the associated toxicity may be species specific and not predictive of a risk in humans. When compared with human systemic exposures at RHD of 20 mg/day the NOAEL in the dog was 4.3 and 6.2 times the human systemic exposures based on AUC0&ndash;24 and Cmax, respectively.</p><p>&nbsp;</p><p><u>Genotoxicity and carcinogenicity</u></p><p>&nbsp;</p><p>Ponesimod did not reveal a genotoxic potential <em>in vitro </em>and <em>in vivo</em>.</p><p>&nbsp;</p><p>Oral carcinogenicity studies of ponesimod were conducted in mice and rats for up to 2 years. In rats, no neoplastic lesions were observed up to the highest dose tested, corresponding with a plasma ponesimod exposure (AUC) which is 18.7 times that in humans at the RHD of 20 mg. In mice, ponesimod increased the combined total incidence of hemangiosarcoma and hemangioma in all treated males and high dose females. The lowest dose tested in females is the no-observed-effect-level (NOEL) for carcinogenesis, and the AUC0-24 is 2.4 times the human systemic exposures at RHD of</p><p>20 mg.</p><p>&nbsp;</p><p><u>Fertility and reproductive toxicity</u></p><p>&nbsp;</p><p>Ponesimod had no effect on male and female fertility in rats at plasma exposures (AUC) up to approximately 18 and 31 times (for males and females, respectively) that in humans at the RHD of 20 mg/day.</p><p>&nbsp;</p><p>When ponesimod was orally administered to pregnant rats during the period of organogenesis, embryo-foetal survival, growth, and morphological development were severely compromised. Teratogenic effects with major skeletal and visceral abnormalities were also observed. When ponesimod was orally administered to pregnant rabbits during the period of organogenesis, a slight increase in post-implantation losses and foetal findings (visceral and skeletal) were noted. Plasma exposure (AUC) in rats and rabbits at the NOAEL (1 mg/kg/day in both species) is less than that in humans at the RHD of 20 mg/day.</p><p>&nbsp;</p><p>When ponesimod was orally administered to female rats throughout pregnancy and lactation, decreased pup survival and body weight gain, and delayed sexual maturation were observed in the offspring at the highest dose tested. Fertility of the F1 females was reduced. The AUC0-24 at the NOAEL of 10 mg/kg/day is 1.2 to 1.5 times that in humans at the RHD of 20 mg/day. Ponesimod was present in the plasma of F1 pups, indicating exposure from the milk of the lactating dam.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Tablet core</u></p><p>&nbsp;</p><p>Croscarmellose sodium</p><p>Lactose monohydrate</p><p>Magnesium stearate</p><p>Microcrystalline cellulose</p><p>Povidone K30</p><p>Silica colloidal anhydrous</p><p>Sodium laurilsulfate</p><p>&nbsp;</p><p><u>Tablet coating</u></p><p>&nbsp;</p><p>Hypromellose 2910</p><p>Lactose monohydrate</p><p>Macrogol 3350</p><p>Titanium dioxide</p><p>Triacetin</p><p>&nbsp;</p><p><em>Ponvory 3 mg film-coated tablets</em></p><p>Iron oxide red (E172)</p><p>Iron oxide yellow (E172)</p><p>&nbsp;</p><p><em>Ponvory 4 mg film-coated tablets</em></p><p>Iron oxide red (E172)</p><p>Black iron oxide (E172)</p><p>&nbsp;</p><p><em>Ponvory 5 mg film-coated tablets</em></p><p>Black iron oxide (E172)</p><p>Iron oxide yellow (E172)</p><p>&nbsp;</p><p><em>Ponvory 7 mg film-coated tablets</em></p><p>Iron oxide red (E172)</p><p>Iron oxide yellow (E172)</p><p>&nbsp;</p><p><em>Ponvory 8 mg film-coated tablets</em></p><p>Iron oxide red (E172)</p><p>Black iron oxide (E172)</p><p>&nbsp;</p><p><em>Ponvory 9 mg film-coated tablets</em></p><p>Iron oxide red (E172)</p><p>Black iron oxide (E172)</p><p>Iron oxide yellow (E172)</p><p>&nbsp;</p><p><em>Ponvory 10 mg film-coated tablets</em></p><p>Iron oxide red (E172)</p><p>Iron oxide yellow (E172)</p><p>&nbsp;</p><p><em>Ponvory 20 mg film-coated tablets</em></p><p>Iron oxide yellow (E172)</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                3 years
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Do Not Store above 30 &deg;C</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The Alu/alu blister with desiccant consists of a laminated Alu cold form film with integrated desiccant and a laminated Alu push-through lidding film.</p><p>&nbsp;</p><p><u>Treatment initiation pack</u></p><p>&nbsp;</p><p>Each blister pack of 14 film-coated tablets for a 2-week treatment schedule contains:</p><p>2 film-coated tablets of 2 mg</p><p>2 film-coated tablets of 3 mg</p><p>2 film-coated tablets of 4 mg</p><p>1 film-coated tablet of 5 mg</p><p>1 film-coated tablet of 6 mg</p><p>1 film-coated tablet of 7 mg</p><p>1 film-coated tablet of 8 mg</p><p>1 film-coated tablet of 9 mg</p><p>3 film-coated tablets of 10 mg</p><p>&nbsp;</p><p><u>Ponvory 20 mg film-coated tablets (maintenance pack)</u></p><p>&nbsp;</p><p>Pack of 28 film-coated tablets or multipack containing 84 (3 packs of 28) film-coated tablets.</p><p>Not all pack sizes may be marketed.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Any unused medicinal product or waste material should be disposed of in accordance with local requirements.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Janssen-Cilag International NV Turnhoutseweg 30
B-2340 Beerse Belgium


            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                5-July-2023
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>